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Abstract 
Optic neuritis (ON) is a common early symptom in multiple sclerosis (MS). It is characterized by 
disruption of the blood-brain barrier (BBB), inflammatory demyelination, and reactive gliosis in 
addition to axonal and somatic degeneration of retinal ganglion cells (RGCs) within the optic nerve 
and retina, respectively. ON can be modelled in animals, in particular by immunization of Brown 
Norway (BN) rats with myelin oligodendrocyte glycoprotein (MOG). In addition to the hallmarks of 
ON, RGC degeneration in BN autoimmune optic neuritis (AON) has been reported to begin  during 
the induction phase of the disease (iAON) prior to lymphocyte infiltration and inflammatory 
demyelination in the optic nerve (Fairless at al., 2012). This may have parallels with observations of 
retinal degeneration in some MS patients even in the absence of clinically defined ON associated 
with demyelination (Green at al., 2010; Saidha et al., 2011). 
Previous studies from our group have shown that this early RGC loss is timed with blood-retinal 
barrier (BRB) disruption, increase in retinal Ca2+ and activation of the Ca2+-activated protease, calpain 
(Hoffmann et al., 2013), with subsequent elevation of optic nerve Ca2+. We hypothesise that an initial 
retinal pathology may lead to Ca2+-mediated cytoskeleton reorganization and axonal transport 
deficits in the optic nerve that could affect axonal integrity, as observed during iAON by electron 
microscopy (Fairless et al., 2012).  
In this study, we examined the potential accumulation of axonal transport proteins along optic 
nerves, with particular focus on the optic nerve head (ONH) where RGC axons are naturally 
unmyelinated and therefore potentially more exposed to stress. No such anomalies were observed 
prior to the appearance of inflammatory demyelinating lesions. However, the axonal actin network 
dynamics within the optic nerve was changed starting iAON. This correlated with a decrease in 
protein expression of the Ca2+-dependent actin binding protein gelsolin, and an increase in fractin, a 
cleaved product of the actin monomer; both proteins being implicated in apoptotic processes. 
Intravitreal injection (IVI) of MK801, an NMDA receptor blocker, during iAON significantly rescued 
RGCs and reverted axonal actin changes to the values observed in healthy animals.  
In order to investigate downstream mechanisms of NMDA activity, a primary RGC culture was 
established. Based on qPCR data that Na+/Ca2+ exchanger 1 (NCX1), involved in regulating Ca2+ 
homeostasis, is elevated during iAON, its role in Ca2+ dynamics of isolated RGCs was investigated. 
Although this primary culture did not fully reflect RGC in vivo pathology (for example, cultured RGCs 
were seen not to retain sensitivity to glutamate excitotoxicity), blockade with an inhibitor targeting 
reverse NCX1 function (SEA0400) significantly reduced Ca2+ responses to glutamate stimulation. 
 
 
However, SEA0400 treatment during iAON in vivo did not affect either RGC survival or optic nerve 
actin dynamics.  
Collectively, data presented in this thesis provide further evidence that early neurodegenerative 
processes involved in AON pathology precede inflammatory driven demyelination of the optic 
nerves. Initial RGC loss observed in iAON is tightly connected to NMDA receptor activity in the retina, 
whereby prolonged intracellular Ca2+ increase may be one of the possible initiators of RGC death. 
These findings could be relevant for the development of potential neuroprotective treatment 
strategies in MS patients, particularly for a sub-set of MS patients characterized by retinal pathology 
in the absence of clinically-defined ON. 
 
Zusammenfassung 
Die autoimmune Optikusneuritis (AON) ist eine der häufigsten Erstmanifestationen einer Multiplen 
Sklerose (MS). Pathophysiologische Merkmale der AON sind Störungen der Bluthirnschranke, 
entzündliche Demyelinisierung und reaktive Gliose sowie axonale und somatische Degeneration von 
retinalen Ganglienzellen. Dabei handelt es sich um die Neurone, deren Axone den Sehnerven bilden. 
Für das Tiermodell der AON werden Brown Norway Ratten mit Myelin-Oligodendrozyten-
Glykoprotein immunisiert. Es konnte gezeigt werden, dass die Degeneration von retinalen 
Ganglienzellen bei der AON schon während der Induktionsphase der Erkrankung (iAON) beginnt und 
zwar bevor Lymphozyten den Sehnerven infiltrieren und es zu einer Demyelinisierung kommt 
(Fairless et al. 2012). Dazu passen Beobachtungen an Patienten mit MS, bei denen eine Degeneration 
der retinalen Nervenfaserschicht nachweisbar ist auch wenn sich klinisch keine AON gezeigt hatte 
(Green et al., 2010; Saidha et al., 2011). 
Vorangegangene Studien unserer Arbeitsgruppe konnten zeigen, dass der frühe Verlust der retinalen 
Ganglienzellen zeitlich parallel mit einer Störung der Blut-Retina-Schranke, einem erhöhten retinalen 
Ca2+-Gehalt und einer Aktivierung der Ca2+-aktivierten Protease Calpain (Hoffmann et al., 2013) 
auftritt. Wir nehmen an, dass die frühe Degeneration retinaler Ganglienzellen zu einer Ca2+-
abhängigen Zytoskelettreorganisation und Axontransportstörung im Sehnerven führt und somit die 
axonale Integrität beeinflusst, was bereits im Stadium der iAON elektronmikroskopisch sichtbar ist 
(Fairless et al., 2012). 
In der vorliegenden Studie untersuchten wir die mögliche Akkumulation von axonalen 
Transportproteinen im Sehnerven, wobei der Fokus der Untersuchungen auf dem Sehnervenkopf lag. 
Dort sind die Axone der retinalen Ganglienzellen natürlicherweise nicht myelinisiert und somit 
 
 
möglicherweise einem erhöhten Stress ausgesetzt. Vor dem Auftreten von inflammatorisch 
demyelinisierenden Läsionen im Sehnerven konnten wir keine Einschränkungen des axonalen 
Transports feststellen. Jedoch fanden sich zu Beginn der iAON Veränderungen in der Dynamik des 
axonalen Aktinnetzwerks. Dies korrelierte mit einer verringerten Proteinexpression des Ca2+-
abhängigen Aktinbindeprotein Gelsolin und der Erhöhung von Fractin, einem Spaltungsprodukt von 
Aktinmonomeren. Beide Proteine spielen eine Rolle bei der Apoptose. Intravitreale Injektionen von 
MK801, einem NMDA Blocker, während der iAON führte zu einem verbesserten Überleben der 
retinalen Ganglienzellen und verhinderte die axonalen Aktin-Veränderungen. 
Um die nachgeschalteten Mechanismen einer NMDA-Rezeptor-Aktivierung in retinalen 
Ganglienzellen zu untersuchen, wurde eine primäre Kultur retinaler Ganglienzellen etabliert. Im 
Rahmen von qPCR-Untersuchungen konnte eine erhöhte Expression des Na+/Ca2+- Austauschers 1 
(NCX1), der beteiligt ist an der Regulation der Ca2+-Homöostase, nachgewiesen werden. Deswegen 
wurden die Ca2+-Dynamiken von isolierten retinalen Ganglienzellen untersucht. Es zeigte sich, dass 
die Primärkulturen nicht die komplette in vivo Pathologie, wie z.B. die Sensitivität gegenüber 
Glutamatexzitoxizität, aufwiesen. Dennoch war es möglich mit Hilfe eines Inhibitors (SE0400), der die 
NCX1 Funktion umkehrt, die Ca2+ Antwort in retinalen Ganglienzellen nach Glutamat-Stimulation 
signifikant zu reduzieren. Allerdings zeigte die Behandlung mit SEA0400 bei iAON im Rahmen einer in 
vivo Studie weder ein verbessertes Überleben retinaler Ganglienzellen noch beeinflusste es die 
Aktindynamiken im Sehnerven positiv. 
Zusammenfassend lässt sich sagen, dass diese Arbeit Mechanismen der frühen Neurodegeneration 
im Rahmen der AON aufzeigt. So ist der frühe Verlust retinaler Ganglienzellen die Folge einer 
Aktivierung von NMDA-Rezeptoren mit konsekutivem Anstieg der intrazellulären Ca2+ 
Konzentration. Auch scheinen Veränderungen im Aktin-Netzwerk das frühe Sterben von retinalen 
Ganglienzellen zu begünstigen. Diese Ergebnisse könnten relevant sein für die Entwicklung von 
potenziell neuen neuroprotektiven Behandlungen der MS. 
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1. Introduction 
1.1 Multiple Sclerosis 
Multiple sclerosis (MS) is the most common cause of chronic neurological disability in young adults 
with an average onset between the ages of 20 and 40 (Hauser and Oksenberg, 2006). MS is seen as 
an immune-mediated demyelinating disease of the central nervous system (CNS) accompanied by 
neurodegeneration that eventually leads to permanent neurological disability. It has become an 
increasingly interesting topic amongst the neurological community considering that it represents a 
great burden on the quality of individual life and society.  
The first disease diagnostic criteria, as well as the correlation of neurological symptoms with post 
mortem CNS pathology, came from the work of “the Father of Neurology” Dr. Jean Martin–Charcot. 
In the late 1860s, he published studies from the autopsy brains of his patients and described and 
illustrated the so–called “la sclerose en plaques” (Charcot, 1868).  By the middle of the 20th century, 
MS was defined as a distinct entity with more known about its diverse neurological outcomes, and 
the first studies on disease origin and risk factors were conducted (Compston & Coles, 2008). 
Unfortunately, even today there are still many unanswered questions regarding the origin, nature 
and pathophysiological mechanisms behind this devastating disease.   
 
1.1.1 Genetics and environmental risk factors in MS 
The origin of MS remains unknown, but the disease seems to be more common amongst certain 
ethnic populations and under specific environmental conditions. MS is recognized as complex genetic 
disorder with modest disease risk heritability and multifaceted gene–environment interactions. 
Genetic heritage as a risk factor emerged after studies on ethnicity (Rosati G., 2001; Langer et al., 
2013) and familial re-occurrence (Sadovnick et al., 1996; Ebers et al., 1995; Ebers et al., 2000). The 
strongest MS susceptibility genes recognized so far are the major histocompatibility complex (MHC) 
class II, DR beta 1 gene (HLA – DRB1), interleukin‑2 receptor complex (IL2R) and interleukin-7 
receptor (IL7R) (Oksenberg et al., 2004; Gregory et al., 2007). In the following years, additional new 
candidates were observed, mostly in immune-related  genes, with some exceptions such as 
ribosomal protein L5, kinesin family member 21B (Kif21B) and GRIN2A gene which encodes the NR2A 
subunit of the N-methyl-D-aspartate receptor (NMDAR; Hafler et al., 2007; Sawcer et al., 2014; 
Baranzini et al., 2009). 
The role of different environmental factors in MS emerged following studies conducted on migration 
(Alter et al., 1978; Rosati, 2001). One prominent environmental risk factor is the Epstein Barr virus 
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(Haahr et al., 2004; Lucas et al., 2011; Ascherio & Munger, 2007a). Other factors include vitamin D 
(Munger et al., 2006; Soilu-Hänninen et al., 2005; Ascherio & Munger, 2007b) and smoking 
(Hedström et al., 2009), etc. All of these, and many other environmental factors, are believed to 
contribute to MS incidence and disease progression, although strong and persuasive evidences are 
still missing.  
  
1.1.2 MS disease course 
Neurological symptoms commonly associated with MS include various physical (weakness, tiredness, 
pain, visual disturbances, etc.), emotional (stress, depression, mood swings, etc.) and cognitive 
(remembering, problem solving, learning, etc.) disturbances. These symptoms represent underlying 
pathological changes in different parts of the CNS whose hallmark is the appearance of inflammatory 
demyelinating lesions (Compston and Coles, 2008). The first attacks are generally unpredictable and 
need to persist for at least 24 hours to be considered as a relapse. Following initial symptoms, MS is 
diagnosed only after the specific McDonald’s criteria are met based on magnetic resonance imaging 
(MRI) examination (Polman et al., 2011).  
The currently used classification of different MS subtypes was established in 2013 by the 
International Advisory Committee on Clinical Trials of MS (Lublin et al., 2014). The following subtypes 
are recognized:  
 
- Clinically Isolated Syndrome (CIS) 
- Radiologically Isolated Syndrome (RIS)  
- Relapsing remitting MS (RRMS) 
- Primary Progressive MS (PPMS) 
- Secondary Progressive MS (SPMS). 
 
CIS is an initial presentation of neurologic symptoms characteristic for MS which does not yet meet 
the aforementioned criteria for a diagnosis of MS (dissemination in time and space). In 80% of MS 
patients, CIS is the first manifestation of disease. Most prominent markers in predicting the 
conversion from CIS to clinically diagnosed MS (CDMS) are MRI lesion load and the presence of 
oligoclonal bands in cerebrospinal fluid (CSF; Kuhle et al., 2015). 
RIS represents the case in which incidental MRI shows the presence of a CNS lesion in the absence of 
clinical symptoms characteristic of MS. RIS might raise the suspicion of MS based on morphology and 
location of the lesions. It was recently evaluated that 33% of people with RIS develop MS within the 
next 5 years (Lebrun et al., 2009). 
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RRMS is the most common MS subtype. Approximately 80% of MS patients are initially diagnosed 
with RRMS (Trapp and Nave, 2008). It has clearly defined attacks (relapses) of new or increasing 
neurologic symptoms that are followed by a remission phase during which symptoms may partially 
or totally disappear (Figure 1.A).  
SPMS commonly follows from a period of RRMS and together they represent the most common 
biphasic MS type. Within 25 years, 90% of RRMS patients progress to SPMS. Relapses can still 
continue with the continuous presence of increasing neurological deficits (Noseworthy et al., 2000; 
Trapp and Nave, 2008; Figure 1.B). 
PPMS is initially diagnosed in around 15% of MS patients. It is characterized by a worsening of clinical 
symptoms without episodes of remission from the beginning of the disease course. Compared to 
RRMS, PPMS patients have more spinal cord than brain lesions (Miller & Leary, 2007; Figure 1.C). 
Based on the heterogeneity of different clinical subtypes and neurological symptoms, it is still 
debatable if what we call MS today is a single disease with many faces or separate phenomena 
classified under the same name (Stys et al., 2012; Lassmann, 2013). 
Optic neuritis (ON) is a syndrome associated with primary inflammation of the optic nerve. It is a 
presenting feature of MS in about 20% of patients, with about 50% incidence at some point during 
the disease course (Balcer, 2006). Reoccurrences of ON in patients that develop MS is around 30% 
during the 10 year follow up (Beck et al., 2004). Clinical symptoms of acute ON associated with MS 
are monocular visual impairments. These include problems in colour distinction (in particular, the red 
colour appears “washed out”), blurry vision or acute vision loss. Pain while moving the eye is 
common in around 90% of patients (Balcer, 2006). ON is diagnosed cinicallz and by measurement of 
visually evoked potentials (Balcer et al., 2015).  
 
 
 
 
 
Figure 1.1.2 MS disease course (adapted from National Multiple Sclerosis Society web page). 
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1.1.3 Pathology of MS 
MS assumes three distinct patterns of CNS pathology: inflammatory demyelination in white matter, 
diffuse pathology in normal-appearing white matter and grey matter demyelination. It is currently 
unclear whether these patterns appear interdependently or independently. 
 
1.1.3.1 White matter pathology 
White matter (WM) lesions have long been considered as a hallmark of MS pathology. These lesions 
are areas of focal demyelination accompanied by blood-brain barrier (BBB) disruption, infiltration of 
lymphocytes and monocytes from the periphery as well as a variable degree of CNS tissue 
destruction. They are highly dynamic structures that change their morphology and inflammatory 
profile with time. In their active state, the centre of the lesion is enriched with inflammatory 
infiltrates which leads to demyelination and, to various extents, the loss of both oligodendrocytes 
and axons. Four different types of WM lesions have been recognized (Lucchinetti et al., 2000).  
Pattern I has the “basic” character shared with all the other lesion types, the presence of 
macrophages and T cells and, to a lesser extent, B cells. Specific for Pattern II is the presence of 
antibody and complement deposition. Patterns III and IV have a common feature of vast 
oligodendrocyte death. The loss of oligodendrocytes in type III lesions is mainly through the process 
of apoptosis while in type IV it is more of a necrotic nature.  Another difference between these two 
types is an uneven loss of different myelin proteins. In Pattern III lesions there is a preferential loss of 
myelin-associated glycoprotein (MAG). The feature of pattern III lesions is having an ill-defined 
shape; in contrast, the other patterns have a well-defined lesion edge which is usually centred 
around the blood vessels. With time, different patterns mature into a more homogeneous, chronic 
state (Breij et al., 2008). These chronic lesions are characterized by a lack of myelin in their centre 
and a redistribution of inflammatory cells (mainly macrophages) at their rims/periphery. In their 
inactive state, the lesion centre is hypo-cellular with a sparse presence of macrophages and 
lymphocytes, but a strong astrocytic gliosis (Kipp et al. 2012). 
Besides these well-established WM lesions recognizable by standard Gd-enhanced MRI examination 
due to the presence of BBB leakage, there are also the so-called “normal-appearing white matter” 
(NAWM) lesions. NAWM pathology is predominantly present in PPMS (Suhy et al., 2000). Hallmarks 
of NAWM lesions include mild BBB disturbances and monocyte infiltration, some activation of 
astrocytes and microglia, and minor demyelination and axonal loss. Interestingly, in NAWM, together 
with the presence of pro-inflammatory and cell damaging markers, many cellular stress markers 
involved in anti-inflammatory and protective mechanisms were also detected (Fu et al., 1998; Zeis et 
al., 2009; Cunnea et al., 2011; Pedre at al., 2011; Graumann et al., 2003). 
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1.1.3.2. Grey matter pathology 
Grey matter (GM) pathology in MS has been largely neglected until recent advances in the sensitivity 
of histopathological markers and MRI provided substantial evidence of its presence and correlation 
with neurological symptoms (Honce, 2013). Lesions have now been observed both in the cortex and 
in the deep GM of the CNS including the caudate nucleus, hippocampus, thalamus, putamen and the 
spinal cord (Haider et al., 2014; Koenig at al., 2014; Gilmore at al., 2008; Vercellino et al., 2009). 
Nonetheless, cortical lesions are now recognised to be a very prominent feature, and are classified 
based on their location (Peterson et al., 2001): 
 
- type1 “leukocortical” lesions – spanning deep layers of GM together with underlying WM 
- type 2 “intracortical” lesions – located entirely within the cortical GM 
- type 3 lesions – located within sub-pial cortical layers, usually not spreading below cortical 
layers 3 and 4 
- type 4 lesions - extend over the entire width of the cortex, do not spread into the subcortical 
WM, and might extend over several gyri or entire lobes. 
 
The inflammatory profile of these lesions is different from their WM counterparts. GM lesions have a 
relative lack of parenchymal lymphocyte infiltration, antibody and complement deposition and BBB 
disruption compared to WM lesions (Peterson et al., 2001; Bö et al., 2003). However, they have 
increased activation of residential microglia and astrocytes (Peterson et al., 2001; Brink et al., 2005; 
van Horssen et al., 2007; Vercellino et al., 2009; Haider et al., 2014; Calabrese et al., 2015).  
Cortical lesions are present during all stages and in all types of MS (Kutzelnigg et al., 2005; Vercellino 
et al., 2005; Lucchinetti et al., 2011). GM pathology has been observed early on following disease 
onset (Dalton et al., 2004; De Stefano et al., 2003; Lucchinetti et al., 2011). Its load accumulates with 
disease progression, sometimes overcoming WM pathology (Kutzelnigg and Lassmann, 2005; Gilmore 
et al., 2008). Interestingly, MS patient disability was shown to correlate better with GM than WM 
pathology (Vercellino et al., 2005; Calabrese et al., 2012; Honce, 2013).  
 
 
1.1.3.3 Pathology of ON 
Optic nerves are the second pair of cranial nerves that belong to the CNS.  They are composed of 
retinal ganglion cell (RGC) axons. These neurons have a distinct compartmentalization of their cell 
bodies, which reside in the innermost layer of the retina and myelinated axons in the optic nerves. 
The initial segment of these axons are unmyelinated and located within the retina forming the retinal 
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nerve fibre layer (RNFL) and the most proximal part of the optic nerve, the optic nerve head (ONH). 
Most of these axons terminate in the lateral geniculate nucleus (LGN) from where further projections 
lead to the visual cortex.  
Similar to WM lesions, the main feature of ON is the presence of inflammatory demyelinating lesions 
in the optic nerve accompanied by visual disturbances (Roed et al., 2005; Söderström et al., 1993; 
Chalmoukou et al., 2015). Due to a lack of published autopsy reports, the pathological mechanisms in 
ON are suggested based on functional testing and MRI. Gd-enhanced MRI confirms BBB breakdown 
(indicative of the presence of inflammatory lesions), while altered visual evoked responses, such as 
prolonged latency and decreased amplitude of the signal imply demyelination and axonal injury, 
respectively. In addition to the pathology in the optic nerve, loss of RGCs and also neurons in the 
inner nuclear layer (INL) together with thinning of the RNFL can be detected in the retina (Green et 
al., 2010; Syc et al., 2012; Kupersmith et al., 2016). Changes in outer retinal parts, such as the outer 
plexiform layer as well as outer nuclear and photoreceptor segments, have also been observed 
(Kaushik et al., 2013; Al-Louzi et al., 2015). Surprisingly, thinning of RGC neuronal and axonal layers 
has even been observed in non-ON eyes of MS patients (Saidha et al., 2011; Walter et al., 2013).  
There are several mechanisms implicated in this observed retinal pathology. On one side, due to 
axonal loss following inflammatory demyelination, it is thought that retrograde trans-synaptic and 
Wallerian-like degeneration, dying of the distal axon following injury, contribute to retinal atrophy 
through depletion of trophic factors coming from the brain (Klistorner et al, 2007; Rocca et al., 2013). 
However, there are findings showing that retinal pathology might originate within the retina itself 
through microcystic macular oedema, and breakdown of the blood-retinal barrier (BRB) with or 
without microglial inflammation, that is associated with INL atrophy (Gelfland et al., 2012; Cennamo 
et al., 2015; Kaufhold et al., 2013).  
Based on the aforementioned pathological observations, it is clear that MS has been dominantly 
characterized through its temporal and spatial inflammatory and demyelinating profile. However, 
additional mechanisms implicated in MS also include autoimmunity, gliosis, and neurodegeneration 
(Stys, 2013). In the last decades, interest in the neurodegenerative aspect of MS has gained 
momentum since many different immunomodulatory therapies have failed to prevent the 
progressive neurological deterioration visible in most MS patients. 
 
1.1.4 Neurodegeneration in MS 
Current disease-modifying therapies have been able to supress inflammatory-mediated relapses, 
although they have proved not to be effective in decreasing or postponing neurological disabilities 
during progressive stages of MS. Neurodegeneration, though observed since the times of Charcot, 
has been neglected in MS research for a long time (Charcot, 1868; Kornek & Lassmann, 1999). 
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However, increasing neurological disability in SPMS and PPMS is found to correlate with the 
accumulation of widespread neurodegeneration and the inability of the CNS to compensate for it 
(Trapp & Nave, 2008). Axonal swellings and transections together with oligodendrocyte stress and 
loss have been detected in post-mortem tissue (Ferguson et al., 1997; Trapp et al., 1998; Ganter et al. 
1999; Lovas et al. 2000). In addition, using MRI and magnetic resonance spectroscopy (MRS), 
neurodegeneration was observed to correlate with decreased levels of N-acetyl-aspartate (NAA), 
mostly present within axons (Matthews et al., 1996; Bjartmar et al. 2000; Fu et al. 1998). Besides 
overall cortical atrophy, more subtle changes such as synaptic loss were also detected (Wegner et al., 
2006; Dutta et al., 2011; Tur et al., 2016; Jürgens et al., 2016). 
Some of the neurodegenerative mechanisms suggested to be involved in MS pathology are (Kwachi 
& Lassmann, 2017; Macrez et al., 2016):  
 
- virtual hypoxia as a consequence of both demyelination and direct action of reactive oxygen 
and nitrogen species (ROS/RNS) 
- glutamate excitotoxicity 
- Wallerian-like degeneration.  
 
In demyelinated axons, “virtual hypoxia” might happen due to an increased pressure on 
mitochondria for adenosine triphosphate (ATP) production. Demyelination leads to a disruption in 
the nodes of Ranvier which in turn causes a redistribution of voltage-gated Na+ channels (NaV). In 
order to maintain efficient conduction velocity in the absence of salutatory action potential 
propagation there is an increase of Na+ influx into the axon. This imposes a higher demand for ATP by 
the ATP-dependent Na+/K+ pump responsible for Na+ extrusion, in turn leading to mitochondrial 
injury through respiratory chain dysfunction (Mahad et al., 2015). In addition, nitric oxide (NO) can 
induce a respiratory burden on the axon. Inducible nitric oxide synthases (iNOS), one of the key 
enzymes involved in NO synthesis is expressed on activated microglia/microphages and is found to 
be upregulated in inflammatory MS lesions (Bö et al. 1994, Liu et al. 2001, Smith & Lassmann, 2002; 
Trapp & Nave, 2008). Elevated NO levels can damage axons by modifying the action of key channels, 
like NaV and Na+/K+ pump (Renganathan et al., 2002; Muriel et al., 2003) and glycolytic enzymes 
(McDonald & Moss, 1993). Activated microglia/microphages are also seen as mediators of oxidative 
damage via production of reactive oxygen species (ROS) contributing further to demyelination and 
free radical-mediated tissue injury (Fischer et al., 2012; Hohlfeld et al, 1997; Stys et al., 2012). 
Astrocytes, the most abundant cells of the CNS, are also associated with neurodegeneration due to 
their impaired function in the suppression of iNOS and in clearance of glutamate (Cambron et al., 
2012). 
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The role for glutamate, the main excitatory CNS neurotransmitter, has been suggested in MS 
pathology since increased levels of glutamate have been detected in all patterns of MS pathology 
(Srinivasan et al., 2005; Baranzini et al., 2010; Tisell et al., 2013; Muhlert et al., 2014). Over 
stimulation of glutamate receptors, expressed on both neurons and oligodendrocytes, is believed to 
cause excitotoxicity predominantly through resultant increases in intracellular Ca2+ to toxic levels. 
Among many other downstream pathways, increased intracellular Ca2+ leads to activation of 
proteases, many of which are involved in the regulation of apoptosis (see chapter 1.11). In active and 
chronic WM lesions, increased levels of Ca2+-activated proteases (calpains) have been detected (Diaz-
Sanchez et al., 2006). The source of elevated extracellular glutamate within inflammatory lesions 
might come from neutrophils, macrophages, microglia and dendritic cells. All of them are capable of 
releasing glutamate through the cysteine/glutamate anti-porter Xc-  (Collard et al., 2002; Pampliega 
et al., 2011; Evonuk et al., 2015; Pacheco et al., 2006; Domercq et al., 2005; Micu et al. 2016). 
Increases in extra-synaptic glutamate from degenerating neurons could cause further injury to other 
neighbouring neurons. Simultaneously, its inappropriate buffering by compromised astrocytes which 
no longer express sufficient levels of membrane glutamate transporters or intracellular enzymes 
involved in maintaining the glutamate-glycine cycle could additionally affect neighbouring neurons 
(Vercellino et al., 2009; Castegna et al., 2011). In NAWM, the axons could also be the source of 
glutamate via inappropriate synaptic vesicle docking and glutamate vesicle release due to axonal 
transport failure. Such axonal glutamate release has been shown to affect oligodendrocytes and to 
disturb normal physiological communication between these two cell types (Micu et al., 2016; Saab et 
al, 2016). 
Wallerian degeneration is a simple experimental model of axonal degeneration following axonal 
transection or crush used to describe the dying back of the distal axonal part in both peripheral 
nervous system and CNS neurons (Waller, 1850). This axonal loss is predominantly thought to occur 
because of the lack of materials delivered via axonal transport from the cell body to the detached 
axon (De Vos et al., 2008; Coleman, 2005). In the CNS, the hallmark of this process is the appearance 
of axonal swellings and spheroids prior to final axonal disruption and the appearance of axonal 
fragments (Beirowski et al. 2010). T cell-mediated axonal transection, hence true Wallerian 
degeneration, has been described in MS, though these events are considered to be relatively rare 
(Trapp et al. 1998). 
Wallerian-like degeneration occurs in many neurodegenerative diseases, especially those where 
axonal transport is impaired (Coleman & Freeman, 2010). Focal axonal swellings are observed to 
occur without overt axonal disintegration and it is debatable if these swellings precede future 
transection or whether they are part of a reversible process that would make them candidate targets 
for neuroprotective strategies. Whatever the precise mechanism of axonal degeneration, axonal 
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spheroids likely contribute to significant functional impairment. There are numerous causes for the 
appearance of axonal spheroids and swellings: focal axolemmal failure with subsequent ionic 
dysregulation causing cytoskeletal damage (Stone et al., 2004; Kornek et al., 2000), local impairment 
of axonal transport (Stokin et al., 2005; Ferreirinha et al., 2004), neuronal autophagy (Komatsu et al., 
2007; Wang et al., 2012), etc. Wallerian-like degeneration is observed to be the most prominent 
feature of early MS axonal loss in WM lesions and NAWM (Rocca et al., 2013; Dziedzic et al., 2010). 
This MS Wallerian-like degeneration was at first connected with demyelinated axons due to the lack 
of glial support (Trapp & Nave, 2008). However, axonal damage was observed in NAWM, and it 
became clear that inflammatory-mediated injury is more wide-spread than previously thought. 
Axonal transport failure could be one of the reasons since certain kinesin superfamily proteins 
involved in axonal transport were found to be decreased in WM lesions and NAWM (Hares et al., 
2016) as well as in non-lesioned GM (Hares et al., 2014).  
It is hoped that through the discovery and understanding of neurodegenerative mechanisms, new 
MS treatment strategies will be developed. This approach is necessary in order to stop or at least 
delay the progression of neurological deficits in MS patients and to improve their life quality. In order 
to achieve this, different animal models of MS have been developed, which have already provided 
tremendous advances in our understanding and anticipation of disease mechanisms. 
 
1.2 Experimental autoimmune encephalomyelitis  
Experimental autoimmune encephalomyelitis (EAE) is the principal animal model used in MS 
research. It can be induced in different animal species (primates and rodents) which results in 
heterogeneous pathological mechanisms similar to those observed in MS - from non-demyelinating 
monophasic clinical disease to secondary progressive neurodegenerative disease (Baker & Amor, 
2012). In most EAE variants, the main pathological feature is the presence of inflammatory, 
demyelinating lesions in the WM (Storch et al., 1998; Kornek et al., 2000). The induction of EAE can 
be achieved by three different mechanisms:  
 
- spontaneous EAE 
- adoptive transfer EAE 
- actively induced EAE  
 
Spontaneous EAE is not a naturally occurring phenomenon but it has been observed in some 
transgenic mice strains, such as transgenic mice expressing a T cell-specific myelin basic protein 
receptor (Goverman et al., 1993; Madsen et al., 1999; Krishnamoorthy et al., 2006).  
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Adoptive transfer EAE is induced by transferring auto-reactive T cells (Ben-Nun et al., 1981). These 
antigen-specific T cells are isolated from the lymph nodes of an animal that previously developed EAE 
and are subsequently injected into a naïve donor. 
Actively induced EAE is initiated after immunization using purified myelin, CNS tissue homogenates, 
or, more commonly, different myelin proteins/peptides, like myelin basic protein (MBP) proteolipid 
protein (PLP) and myelin oligodendrocyte glycoprotein (MOG). Such active immunizations usually 
require the use of adjuvants to boost the immune response and in some cases additional injection of  
Bordetella pertussis-derived toxin is required in order to facilitate break-down of the BBB (Linthicum 
et al., 1982) and expansion of autoreactive T cells (Hofstetter et al., 2002).  
 
1.2.1 MOG-induced EAE in Brown Norway rats 
In most animal strains, EAE pathology is driven by T cells while the activation of the humoral immune 
system, commonly observed in MS, is missing (Krishnamoorthy and Wekerle, 2009). The Brown 
Norway (BN) rat strain was previously declared as resistant to the development of EAE following 
immunizations with guinea pig CNS homogenate and some myelin proteins (Gasser et al., 1973). 
However, it was later shown to be highly susceptible to EAE induction by immunisation with MOG. 
This resulted in an extensive antibody-mediated demyelinating pathology, occurring in both the 
spinal cord and optic nerve due to the high expression of MOG within these structures. This strong 
humoral immune component is attributed to the genetic background of BN rats which have different 
RT1 haplotypes to other rat strains, but are analogous to the MHC in humans (Stefferl et al.; 1999). 
The pathological profile in spinal cords of BN rats resemble that observed in MS (Kornek et al., 2000). 
The incidence of autoimmune optic neuritis (AON) in this model is about 90% of all animals that 
develop neurological symptoms indicative of spinal cord pathology (Meyer et al., 2001; Fairless et al., 
2012). It shares common features with those observed in human ON, including inflammatory 
demyelinating lesions (Meyer et al. 2001) accompanied by retinal atrophy (Hein et al., 2012), RGC 
loss and visual deterioration (Meyer et al., 2001). In this model, the loss of RGCs precedes classical 
optic nerve pathology (Hobom et al., 2004; Fairless et al., 2012) and BBB leakage (Boretius et al., 
2008). This finding makes the BN-EAE model important in addressing the retinal neurodegenerative 
mechanisms that might mimic pathology detected in MS patients. This is especially true due to 
potential correlation with RGC degeneration observed in the non-ON eyes of MS patients – see 
chapter 1.3.4.  
Recent work on this model included the investigation of the origins and downstream molecular 
pathways involved in AON pathology, therefore with focus on the mechanisms involved in mediating 
the earliest neurodegenerative events prior to onset of classical optic nerve lesion formation. AON 
can be separated into two phase: the induction AON (iAON) during which RGC loss, microglial 
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activation and disruption of BRB was observed; followed by the clinical AON (cAON) with 
inflammatory optic nerve lesions formation and demyelination. Some of the mechanisms that could 
be involved in early RGC loss might originate from the observed BRB disruption and activation of 
microglia and astrocytes within the retina as well as in the ONH (Fairless et al., 2012). Though at this 
time point optic nerves seem unchanged, ultrastructural modifications were detected in their still 
myelinated axons such as vacuolization of the peri-axonal space (Fairless et al., 2012) and disruption 
of axonal domains (Stojic, PhD thesis 2016). Dynamic intracellular connection between the two 
compartments, retina and optic nerve, is established through axonal transport that rely on 
cytoskeleton integrity. Axonal cytoskeleton and transport changes in BN AON require investigation in 
order to see whether neurodegenerative mechanisms similar to those observed in MS are occurring 
(see chapter 1.1.4 – Wallerian-like degeneration) and also whether this might serve as a link between 
observed retina/ONH disturbances and further upstream disruptions in the axonal cytoskeleton. 
Indeed in iAON, breakdown of the cytoskeletal component spectrin and de-phosphorylation of 
neurofilaments in the optic nerves have been previously reported (Hoffman et al., 2013; Stojic, PhD 
thesis 2016).  
Further on, early RGC loss in iAON was shown to be apoptotic in nature (Fairless et al., 2012) and this 
loss was observed to correlate with increased Ca2+ tissue levels in both retina and optic nerves. 
Systemic application of calpeptin, a blocker of calpain – a Ca2+-dependent protease, was shown to 
ameliorate disease severity and axonal loss during clinical inflammatory demyelination of optic 
nerves and also to protect RGCs during both induction and clinical phases of AON (Hoffmann et al., 
2013).  These findings opened the question of the role of Ca2+ increases in both RGC loss and axonal 
integrity. What initiates these observed Ca2+ increases; is this phenomenon happening 
simultaneously in both retina and optic nerves; or alternatively does the initial insult originate within 
one compartment with subsequent disturbances progressing in an anterograde or retrograde 
direction? In the case of retinal Ca2+ increase, glutamate excitotoxicity, one of the neurodegenerative 
mechanisms implicated in MS (see chapter 1.1.4 – glutamate excitotoxicity), may be involved. RGC 
loss might be initiated and accompanied via intracellular Ca2+ increase following overstimulation of 
RGC glutamate receptors. Further on, this Ca2+ increase could diffuse and initiate axonal 
degeneration. However, extracellular glutamate increase could also originate within RGC axons, 
following synaptic vesicles docking and glutamate vesicular release along the axons due to upstream 
axonal transport deficits in the ONH.  
The relevance of EAE models and mechanisms involved in EAE pathology to the ones suggested for 
MS is confirmed by the current success of immunomodulatory MS therapies, like Natalizumab 
(Yednock et al., 1992; del Pilar Martin et al., 2008; Stüve et al., 2006) or FTY720 (Fujino et al., 2003; 
Kappos et al., 2010). However, immunomodulation has not been able to address the persistent 
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problem of ongoing neurodegeneration, and currently no neuroprotective therapies are available to 
MS patients. And thus, the quest to better understand neurodegenerative processes under an 
autoinflammatory environment continues to be as relevant as ever. 
 
1.3 Axonal cytoskeleton and transport 
1.3.1 Axonal cytoskeleton 
Neuronal maintenance and physiological functioning depends on and is influenced by the state of its 
axonal cytoskeleton and transport infrastructure. Proteins which form the cytoskeleton exist as 
either free cytosolic monomers or are assembled into highly dynamical structures that form and 
support the axon. The three main constituents of the (axonal) cytoskeleton are (Figure 2): 
-  Neurofilaments (NFs) belong to the family of intermediate filaments and contribute to radial 
axonal growth (axonal diameter) and consequently axonal conductance (Yuan et al., 2012). 
NFs are composed of three polypeptides: light (NFL, 60 – 70 kDa; Fliegner & Liem, 1991), 
medium (NFM, 130 – 170 kDa) and heavy (NFH; 180 – 200 kDa) chains, defined by molecular 
weight, which form complexes with α-internexin (Yuan et al., 2006). Under normal 
physiological conditions in myelinated axons, NFs are phosphorylated on their side arms 
(Pant, 1995). They have been implicated in different neurodegenerative diseases, such as 
amyloid lateral sclerosis (ALS), where NF accumulation is the hallmark of disease pathology 
(Rudrabhatla, 2014). In MS, the presence of non-phosphorylated NFs in axons is considered 
to be a stress marker and is readily observed in demyelinated, swollen and transacted axons 
(Trapp et al., 1998). 
- Microtubules are seen as long-term railways for the transport of organelles and vesicles. 
Microtubule filaments are dynamic, ATP-dependent heterodimers composed of α and β-
monomer tubulin subunits (both ~ 50 kDa; Fletcher & Mullins, 2010). There are different 
proteins involved in microtubule stabilization. Tau is one of them, and has been implicated in 
neurodegenerative diseases, where its hyper-phosphorylation and accumulation is 
considered the cause of neurodegenerative processes in Parkinson’s (PD) and Alzheimer’s 
(AD) disease (Rudrabhatla, 2014). In MS, though not considered to be the primary cause of 
neurodegeneration, tau accumulation has also been observed (Anderson et al., 2008).   
- The Actin network consists of filamentous actin (F-actin) built from ATP-dependent binding 
of globular monomeric, 42 kDa protein (G-actin; Fletcher & Mullins, 2010). A third structure 
has been recently described – ring-like structures of actin and spectrin spaced at intervals of  
~180 nm, known as actin rings. They have been detected in the axonal initial segment, 
dendrites and at the Nodes of Ranvier (Xu et al., 2013; Lukinavičius et al., 2014; D’Este et al., 
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2015). Actin has been implicated in diseases like PD and Down’s syndrome (Bernstein et al., 
2011). In MS patients, levels of blood gelsolin, one of a family of actin-severing proteins, was 
found to be decreased (Kułakowska et al., 2010), and the presence of actin in CSF is found to 
correlate with disease neurological severity (Semra et al., 2002).  
 
 
1.3.2 Axonal transport  
Axonal transport is one of the ways a neuronal cell body communicates with its dendrites, axons and 
their synapses. The axonal transport machinery involves “transport rails” consisting mainly of 
microtubule filaments, the ATP-dependent motor proteins kinesin and dynein as “transport engines”, 
and transported proteins and organelles as “transport cargo”. Briefly, axonal transport is divided 
based on the average rate of movement into a fast component (FC, 50 - 400 mm/day) and two 
subtypes of slow component (SCa 0.2 - 3 mm/day; SCb 2 - 10 mm/day) (Black, 2016). FC is associated 
with microtubule ATP-dependent kinesin/dynein transport of membranous organelles, like 
mitochondria and synaptic vesicles. SC involves the transport of proteins that make up the 
cytoskeleton and cytosol of the axons (Dahlström et al., 1992; Brown, 2009). Axonal transport 
depends simultaneously on cell body viability to synthesise proteins that are then transported 
further on, their attachment to kinesin/dynein, mitochondrial respiration for ATP needs and finally 
cytoskeletal stability. 
Some neurodegenerative diseases as a main pathological hallmark have lesions with misfolding, 
fibrillization and aggregation of disease-specific proteins that affect axonal transport. In the ALS 
animal model, it has been shown that an anomaly in the SOD1 gene leads to axonal transport deficits 
Figure1.3.1. Cell cytoskeleton. (copyright ©Sinauer Associates Inc. 2001) 
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through damage to both the mitochondria (De Vos et al., 2007) and the cargo through the promotion 
of cargo disassembly from transport motors (Jung et al. 2005,Wagner et al. 2004). In AD, β-Amyloid 
(Aβ) peptides that result from amyloid precursor protein (APP) cleavage, accumulate along the axons 
where they damage transport through affecting different cargoes and mitochondria (Hiruma et al. 
2003, Rui et al. 2006). The microtubule-binding protein tau has been also found to interfere with 
kinesin-microtubule binding (Seitz et al. 2002). In MS, axonal swelling, blebbing and transection are 
detected, with accumulation of β-Amyloid precursor protein (βAPP) and SMI32 markers (Ferguson et 
al., 1997; Trapp et al., 1998). In addition, a decrease in the transport motor protein kinesin was 
detected within, and in the vicinity of, demyelinating lesions (Hares et al., 2016). 
 
1.3.3 Cytoskeleton and transport deficits in EAE 
Axonal damage in EAE has been shown to be of heterogeneous origins. In general, axonal transection 
following inflammatory demyelination is considered to be the main cause of axonal degeneration 
(Trapp & Nave, 2008). Demyelinated axons are perceived as more vulnerable since they are exposed 
to potentially disruptive agents coming from the inflammatory cells and damaged oligodendrocytes. 
This can lead to mitochondrial damage and axonal transport deficits, and induction of spheroid 
formation leading to axonal transection. Some of these pathological events have been observed in 
the EAE model. In the adoptive transfer EAE model with autoreactive MBP-primed T cells, it was 
shown that T cells are the main mediators of axonal damage (Shriver et al., 2006). In another study, it 
was shown that microglial activity following breakdown of the BBB and fibrinogen leakage was the 
main driver of axonal damage (Davalos et al., 2012). The increased presence of ROS/ reactive 
nitrogen species (RNS) has been found to interfere with mitochondrial transport along axons within 
inflammatory lesions. However, axonal transport deficits have also been found to precede 
demyelination and axonal degeneration (spheroid formation and transection). This implies that 
inflammatory damage might be more widespread than previously though and could affect the 
transport machinery prior to demyelination. More importantly, axonal transports deficits were 
reversible in morphologically normal-appearing axons which are of great importance in developing 
potential therapeutic strategies (Nikic et al., 2010; Sorbara et al., 2014). In the AON model, following 
inflammatory demyelination, accumulation of voltage-gated Ca2+ channels was observed along 
axonal tracts. Additionally, application of a channel blocker increased the survival of healthy axons, 
having higher efficiency if applied during the iAON, prior to clinical optic nerve pathology. It was 
subsequently suggested that premature docking of channel-bearing vesicles along the axon might be 
an early sign of axonal transport deficits (Gadjanski et al., 2009).  
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1.4 RGC death in experimental models 
Understanding neurodegenerative pathways in complex animal models like EAE-AON where various 
inflammatory and neurodegenerative mechanisms happen in parallel, influencing each other in both 
suppression and promotion, might not be possible without comparison with more controlled 
neurodegenerative models, like optic nerve transection and intravitreal injection (IVI) of glutamate-
receptor agonists.   
 
1.4.1 Optic nerve injury 
The most widely-used model to investigate molecular pathways involved in axonal degeneration and 
transport deficits and their influence on neuronal viability is optic nerve transection. Activation of 
apoptotic cell death pathways are observed in RGCs following nerve transection. The main reason for 
retrograde RGC cell death is connected with the loss of retrograde-trophic support coming from the 
brain. Indeed, phosphorylation of Akt via phosphoinositide 3-kinase (PI3K), an anti-apoptotic 
pathway dependent on trophic receptor stimulation, was shown to be reduced in RGCs after in vivo 
axotomy (Kermer et al., 1999). Also, caspase activity and DNA fragmentation were observed (Kermer 
et al., 1999).  Bax family proteins (Bcl-2 and Bax), which play an important role in regulation of 
apoptosis, were found to be upregulated in retina following optic nerve crush (Isenmann & Bähr, 
1997).  
In models of nerve injury, the axonal compartment also goes through dynamic changes. In an in vitro 
model of axonal transection, the distal part of the axon goes through a process known as Wallerian 
degeneration (see chapter 1.1.4). Following transection, the initial phase is characterized by the 
formation of axonal spheroids - this morphological change is accompanied by high Na+ and Ca2+ influx 
through different ion channels (George et al., 1995), massive cytoskeleton reorganization through 
calpain-mediated mechanisms and lysosomal activity (Billger et al. 1988; Johnson et al. 1991; 
Kerschensteiner et al., 2005; Knöferle et al., 2010). The whole process is referred to as axonal 
apoptosis, since it is highly organized and controlled in nature (Wang et al., 2012).  
 
1.4.2 Glutamate excitotoxicity in the retina  
Following pre-synaptic glutamate release, activation of ionotropic (N-methyl-D-aspartate, NMDA; α-
amino-3-hydroxyl-5-methyl-isoxazol-4-propionic acid, AMPA and kainate) and metabotropic (mGlu) 
glutamate receptors leads to intracellular increases in Na+ and Ca2+ ions which leads to the 
depolarization of the post-synaptic neuron (Hare et al., 2011). However, upon overstimulation of 
glutamate receptors, toxicity can also be induced, termed glutamate excitotoxicity, due to the 
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elevation of Na+ and Ca2+ to toxic levels capable of activating downstream pathways leading to cell 
death (Olney, 1969; Obrenovitch et al., 2000). Glutamate excitotoxicity first emerged as a as concept 
following studies on neonatal mice where subcutaneous injection of glutamate led to neuronal loss, 
preferentially in the inner retina and hippocampus (Lucas & Newhouse, 1975; Olney et al., 1969). In 
general, almost all glutamate receptor subtypes are confirmed to be involved in mediating 
excitotoxicity, but ionotropic receptors are recognized as the key players in this process (Choi, 1988; 
Tymianski, 1996).  
In the retina, glutamate excitotoxicity can be induced following IVI of toxic levels of glutamate 
receptor agonists (NMDA, AMPA and glutamate; Siliprandi et al., 1992; Pellegrini & Lipton, 1993; 
Pang et al., 1999; Luo et al., 2001; Chidlow et al., 2008). RGCs are especially vulnerable since it is 
known that these cells have a high density of glutamate channels on their dendrites (Aizenman et al., 
1988; Massey & Miller, 1990; Diamond & Copenhagen, 1993). Besides RGC apoptosis, changes in 
their axonal compartments were also observed following IVI of NMDA (Saggu et al., 2010; 
Kuribayashi et al., 2010). 
 
1.4.3 RGC loss in AON 
In the model of AON, the initial insults and downstream pathways of RGC degeneration are currently 
not clear. In AON, evidence for both primary and secondary RGC death has been observed. 
Secondary RGC death refers to retrograde cell body loss following axonal injury – such as that which 
occurs following axotomy – and is observed during cAON, where it is connected with inflammatory 
demyelination in the optic nerve. During this disease stage, both axonal loss and accompanying Ca2+ 
increases of the optic nerve, and more specifically the axons, could be detected (Gadjanski et al., 
2009; Hoffmann et al., 2013). In addition to the reduction in surviving RGCs at this stage of the 
disease, evidence of neurodegenerative pathways being activated in RGCs include positivity for Bax 
and capase-3 (Hobom et al., 2004), and also DNA degradation as detected by TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labelling) (Fairless et al., 2012). 
In AON, a case for primary RGC death has been made for that occurring during iAON, since during 
this period inflammatory demyelination and axonal injury in the optic nerve are not observed to 
occur, and thus no clear mechanism of secondary degeneration is apparent. Additionally, despite no 
pathological changes being seen in the optic nerve, retinal disturbances such as increased 
permeability of the BRB and activation of resident microglia could be seen which may directly affect 
the integrity of the RGC soma. Although RGC degeneration is much less in iAON than that seen during 
the later cAON, similar apoptotic signalling could be seen (Hobom et al., 2004; Fairless et al., 2012). 
Glutamate excitotoxicity might be implicated in primary RGC loss during iAON. Treatment with 
minocycline, an anti-inflammatory and neuroprotective antibiotic, was shown to reduce glutamate 
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levels in the retina already in iAON correlating with protection of RGCs against degeneration (Maier 
et al., 2007). In addition, systemic application of memantine and MK801 (NMDA-receptor blockers) 
were shown to be neuroprotective when applied during both iAON and cAON (Sühs et al., 2014). In 
addition, elevated Ca2+ levels in both retina and optic nerves were observed during AON implying the 
role of Ca2+ in early RGC loss (Hoffmann et al., 2013).  
 
1.5 The role of Ca2+ in neurodegeneration 
Ca2+ is the main intracellular secondary messenger of all eukaryotic cells including neurons. It 
regulates some of the most important cellular physiological functions: membrane excitability 
(Krnjevic et al., 1989; Schwartzkroin & Stafstrom, 1980), cytoskeletal integrity (Schlaepfer & 
Zimmerman, 1985; Trifaro & Vitale, 1993), exocytosis and synaptic activity (Robitaille et al, 1993; 
Llinas et al., 1992; Smith & Augustine, 1988) and gene expression through nuclear signalling (Bading, 
2013). To maintain intracellular Ca2+ homeostasis, neurons must be able to control the influx of 
extracellular Ca2+ which is about 100,000 times higher than intracellular cytosolic Ca2+. Because of 
this high Ca2+ gradient and the need for homeostasis, neurons have very sophisticated machinery to 
regulate Ca2+, including control of its: influx (ion channels), buffering (Ca2+-binding proteins, 
endoplasmic reticulum and mitochondria), intracellular diffusion, internal storage (endoplasmic 
reticulum and mitochondria) and its efflux (ionic pumps) (Tymianski & Tator, 1996).  
In addition to the role of glutamate receptors as described above, Ca2+influx is also connected with 
voltage-gated Ca2+ channels (VGCC), while its efflux is mostly regulated by plasma membrane Ca2+ 
ATPases (PMCA) and the Na+-Ca2+ exchangers (NCX).  
 VGCC classification is based on their physiological properties and sensitivity to known toxins: 
high voltage-activated, Cav1.1-4 channels, Cav2.2 (N-type) and Cav2.1 (P/Q-type); 
intermediate voltage-activated, Cav3.1-2 and Cav3.3 (T-type) and low voltage-activated, 
Cav2.3 channel (R-type; Catterall et al., 2005). In RGCs, all types of VGCCs were detected 
(Karschin & Lipton, 1989; Taschenberger & Grantyn, 1995). Following various insults, 
blockade of different VGCC types have been shown to be neuroprotective, through decrease 
of Ca2+ influx. In EAE, VGCCs were observed to be expressed on axons within inflammatory 
demyelinated lesions (Kornek et al., 2001). Bepridil-treated animals (a non-specific VGCC 
blocker) ameliorated EAE disease severity through reduced inflammation and axonal 
pathology (Brand-Schieber et al., 2004). Specifically, the N-type blocker ω-conotoxin was 
shown to reduce EAE disease severity and protect axons in both the optic nerves and the 
spinal cord. In optic nerves, this blocker significantly decreased the signal intensity of Mn2+-
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enhanced MRI, indicating a reduction in Ca2+ in optic nerve tissue. The same blocker 
significantly decreased intra-axonal Ca2+, detected in vivo using a Ca2+ sensitive dye 
(Gadjanski et al., 2009). In the optic nerve crush model, application of the L-/N-type channel 
blocker amlodipine and a T-type channel blocker ameliorated intra-axonal Ca2+ elevation 
(Knöferle et al., 2010). Application of the PhTx3-4 spider toxin, targeting both N- and P/Q-
types, was neuroprotective in the retina following IVI of NMDA, and was particularly 
effective in decreasing RGC loss (Binda et al., 2016). On isolated RGCs, application of VGCC 
blockers decreased initial Ca2+ influx, following glutamate receptor stimulation (Hartwick et 
al., 2008). 
 PMCA is a transport protein existing as four isoforms, PMCA1-4, derived from different genes 
and modified further by alternative splicing (Carafoli, 1997). PMCA is considered to be a 
channel with high Ca2+ sensitivity but a low capacity for Ca2+ extrusion (Brini & Carafoli, 
2011). Thus, it appears to operate well during physiological conditions where intracellular 
calcium levels are low. In hippocampal neurons following glutamate-induced apoptosis, 
PMCA was shown to be cleaved by caspases leading to further Ca2+ increases and a 
subsequent switch from apoptotic to necrotic cell death (Schwab et al., 2002). Different 
levels of PMCA types were found expressed on retinal cells, with dominant PMCA2 and 
PMCA3 expression on RGCs (Krizaj et al, 2002). In EAE spinal cords, decreased levels of 
PMCA2 mRNA were implied to contribute to neuronal loss (Nicot et al., 2003).  
 NCX plasma membrane family includes three types NCX1-3, denoting three different genes 
that encode them (Annunziato, 2013). NCX is considered to be a channel of low Ca2+ 
sensitivity but high capacity for Ca2+ extrusion (Brini & Carafoli, 2011). Thus, it requires high 
Ca2+ levels for activation, but then functions very efficiently – suggesting that, unlike the 
PMCA, this pump may function best during pathophysiological conditions. NCX functioning is 
dependent on the net electrochemical gradient across the plasma membrane and can 
operate in two modes, Ca2+ entry (forward) or Ca2+ exit (reverse) mode. “The Ca2+ entry mode 
of exchange is usually identified as an internal Na+-dependent Ca2+ influx and an external 
Ca2+-dependent, ouabain-insensitive Na+ efflux. The Ca2+ exit mode of exchange is defined 
operationally as an external Na+-dependent Ca2+ efflux and an internal Ca2+-dependent 
ouabain and tetrodotoxin - insensitive Na+ influx” (Blaustein & Lederer, 1999). The discovery 
of NCX was preceded by experiments in which Na+ and Ca2+ competition across the plasma 
membrane could not be explained without the existence of a new channel with the 
aforementioned physiological properties. In the 1960s, the existence of such a channel was 
proposed in different tissues such as cardiac muscle (Glitsch et al., 1970) and invertebrate 
neurons (Baker et al., 1969). Due to its co-dependence on intra- and extra-cellular Ca2+ and 
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Na+, NCX was seen as a double-edged sword when it comes to neuronal protection. In 
normal physiological conditions, synaptic activity or axonal depolarization, it is assumed to 
work in its forward mode, extruding Ca2+ together with the PMCA from the neuronal cytosol. 
However, in neuronal cultures following glutamate stimulation, NCX reverse mode of action 
was observed (Hoyt et al., 1998; Bano et al., 2005; Araujo et al., 2007; Brittain et al., 2012). In 
cerebral ischemia (Formisano et al., 2013) or following IVI of NMDA (Inokuchi et al., 2009), 
NCX was observed to contribute to neuronal loss. In EAE, NCX Ca2+-driven influx was 
connected with NaV channel co-expression along damaged axons (Craner et al., 2004b). 
When it comes to NCX blockers, there are two blockers commonly used capable of 
predominantly targeting its reverse operation: KB-R7943, which has the limitation that it 
does not distinguish between different NCX types, and also has been shown to affect 
mitochondrial function (Brustovetsky et al., 2011); SEA0400, however, is assumed to affect 
predominantly the NCX1 type (Matsuda et al., 2001), with fewer off-target effects. Systemic 
application of SEA0400 leads to RGC protection following IVI of NMDA and ischemia-
reperfusion (Inokuchi et al., 2009). 
 
1.5.1 The role of Ca2+ in apoptosis 
Deregulation of intracellular Ca2+ homeostasis shapes the response of cellular effectors, such as 
endoplasmic reticulum (ER) and mitochondria, which can lead to activation of both pro- and anti-
apoptotic pathways (Pinton et al., 2008).  
Ca2+-mediated ER stress, which results in protein misfolding and consequently apoptotic cell death, 
can be initiated by both Ca2+ depletion and overload of ER Ca2+ pools. This may happen following 
changes in the Ca2+ transport systems (sarco-ER Ca2+ ATPase and Ins(1,4,5)P3 receptors). Prolonged 
ER stress eventually leads to the enhancement of caspase-12 activity, present on the ER membrane, 
which is cleaved (activated) by m-calpains. Once activated, caspase-12 acts on effector caspases to 
induce apoptosis (Nakagawa et al., 2000). ER proteins are also reported to interact with the Bcl-2 
family of proteins which are the key regulators of apoptotic cell death (Baffy et al., 1993).  
The relationship between Ca2+ deregulation and mitochondria in the process of apoptosis can be 
two-sided. Mitochondria are capable of sequestering high amounts of intracellular Ca2+ under 
(patho)physiological conditions in spite of the low affinity of their transporters. The close proximity 
of mitochondria to ER and plasma membrane enables activation of their transporters following high 
micro-domain Ca2+ increases (Pinton et al., 1998; Thor et al., 1984). That is why mitochondria were 
mostly seen as an anti-apoptotic factor in Ca2+ mediated apoptosis. The main role of mitochondria in 
the process of apoptosis is connected to the permeabilization of the outer mitochondrial membrane, 
release of cytochrome c and further activation of effector caspases. In this process, Ca2+ increase 
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does not play a direct role (Carafoli, 2002). However, in pro-apoptotic settings, mitochondrial Ca2+ 
increases via Ins(1,4,5)P3 receptors promotes the opening of the transition permeability pore (PTP) 
and further induces the release of cytochrome c (Szalai  et al., 1999; Crompton, 1999). 
Finally, many Ca2+-activated cytosolic factors are involved in the process of apoptosis: calcineurin, 
nitric oxide synthase, endonucleases, phospholipases and proteases (Orrenius et al., 20003). Ca2+ 
influx through ion-specific channels or following Na+ influx and subsequent reverse function of NCX 
(Baruskova et al., 2012; Staal et al., 2010) can activate calpains (Ma et al., 2013; Yang et al., 2013). 
Cellular substrates of calpain include many cytoskeleton proteins such as ankyrin, spectrin, NFs, ion 
channels and some caspases involved in apoptotic cell death (Goll et al., 2003). 
 
1.5.2 Apoptotic and Ca2+ dependent modulation of actin cytoskeleton  
Under normal physiological conditions, the actin network is in a dynamic balance between assembly 
and disassembly. There are several mechanisms involved in regulating this balance: tread-milling, 
severing and whole filament destabilization (Brieher et al., 2013). However, in the case of cell injury 
these mechanisms can become over-pronounced resulting in irreversible actin network disassembly. 
Mounting evidence indicates that actin is at the same time both a sensor and a mediator of apoptosis 
(Desouza et al., 2012; Franklin-Tong & Gourlay, 2008). The extent of actin and microtubule 
cytoskeleton damage was shown to be a good predictor of the activated cell death pathways: 
apoptosis or necrosis (Adamec et al., 2001). In human neutrophil cultures, following induction of 
apoptosis, actin monomer cleavage was observed following Ca2+ increase and calpain activation 
(Brown et al., 1997). During apoptosis, activated caspases were also found to induce G-actin 
cleavage. Caspase-cleaved products of G-actin include N-terminal actin, 32 kDa (fractin) and 15 kDa 
(tActin) fragments (Sokolowski et al., 2014; Utsumi et al., 2003). In oligodendroglial progenitor cells, 
fractin was found to be not only a morphological apoptotic marker but also to have a functional role 
in apoptotic signalling (Schulz et al., 2009). 
Actin network stability was shown to be affected through F-actin disassembly following intracellular 
Ca2+ increase (Neely and Gesemann, 1994; Furukawa et al., 1995) and NMDA receptors stimulation 
(Halpain et al., 1998). At the same time, F-actin stability affects, via a feed-forward loop, Ca2+-
permeable channels. In addition, F-actin inhibited the function of isolated PMCA from human 
erythrocytes, whilst G-actin and/or short oligomers caused its activation (Vanagas et al., 2013). 
Cardiac NCX1 attachment to the plasma membrane is also directed via F-actin, and channel reverse 
mode of action was observed to be dependent on the actin network polymerization state (Condrescu 
& Reeves, 2006). F-actin depolymerisation was found to reduce Ca2+ influx following NMDA receptor 
stimulation (Rosenmund & Westbrook, 1993). This implies that the actin cytoskeleton is, besides 
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mediating channel docking and support, also an active regulator of Ca2+ dynamics through 
modulating channel permeability properties.  
Following Ca2+ increases, F-actin disassembly can be mediated, amongst other pathways, via the Ca2+-
dependent actin-severing protein, gelsolin. Gelsolin was found to be a Ca2+-induced anti-apoptotic 
factor (Harms et al., 2004). In genetically manipulated mice that lacked gelsolin, following excitotoxic 
NMDA receptor stimulation, increased Ca2+ influx was reported (Furukawa et al., 1997). Having this in 
mind, gelsolin might be seen as a protective factor during apoptotic Ca2+ increases. However, gelsolin 
itself is targeted and cleaved by caspases, and the resultant cleaved product, N-terminal gelsolin, was 
observed to correlate with morphological changes associated with apoptosis (Kothakota et al., 1997).  
In the case of iAON, early calpain activation was shown to correlate with increased Ca2+ levels in the 
retina as indicated by Mn2+-enhanced MRI, followed by subsequent calpain and calcium changes in 
the optic nerves (Hoffmann et al., 2013). This opens many questions concerning “primary” 
neurodegenerative events in axonal loss during AON. A current hypothesis could be that a primary 
retinal insult resulting in retinal Ca2+ increases with subsequent calpain activation and degradation of 
components of the actin cytoskeleton (as indicated by spectrin degradation - Hoffmann, et al., 2013), 
in turn may spread anterogradely to the optic nerves through a dysregulation of actin-controlled 
mechanisms, further contributing to axonal damage.   
 
1.6 Summary 
In summary, ON in MS patients and AON in BN rats share several features in common, including RGC 
degeneration. To date, these degenerative processes and their causes are not fully clear but there 
are evidences that an initial insult might originate within the retina (or the optic nerve head). This 
primary insult could come from BRB disruption and retinal signals that could activate pro-
inflammatory microglial phenotype and disturb astrocyte-synapse function. This primary retinal 
injury would be independent from later retinal retrograde damage coming from injured axons 
following inflammatory lesions formation in the optic nerve. The early retinal pathology in MS is 
supported by the observation of retinal RNFL thinning in the eyes of MS patients lacking any clear 
optic nerve pathology (Saidha et al., 2011; Walter et al., 2013). In AON, a role for Ca2+ in these initial 
changes has been highlighted through both MRI and Ca2+ imaging experiments (Gadjanski et al., 
2009; Hoffmann et al., 2013). In addition, the role of the Ca2+-activated protease, calpain, whose 
activity correlates with the timing of Ca2+ elevation, has been demonstrated by pharmacological 
inhibition (Hoffmann et al., 2013). Calpain is known to target structural components involved in 
axonal transport and the maintenance of cytoskeletal integrity, and disturbances in these 
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compartments have been suggested based on the visualization of βAPP accumulation in damaged 
axons, disturbed axonal ultrastructure as seen by electron microscopy, and breakdown of the actin-
anchoring protein, spectrin. It remains to be determined whether a primary retinal insult can account 
for the observable pathology, particularly with respect to the optic nerve, and which  Ca2+-activated 
cascade are involved in the mediation of RGC degeneration. Understanding of these early processes 
in AON may allow for neuroprotective strategies to be developed with translational potential to 
reduce the burden on MS patients caused by on-going neurodegeneration which can continue even 
during immunomodulatory handling. 
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2 The aim of the study 
Neurodegeneration in MS correlates with neurological disability in MS patients. Some features of 
pathological mechanisms behind immune-mediated neuronal loss can be predicted based on MRI 
and tissue autopsy. However precise mechanisms cannot be answered without the use of animal 
models and in vitro studies. AON was shown to be a suitable model for investigating 
neurodegenerative processes assumed to be involved in MS ON. Adaptive, humoral and innate arms 
of the immune system are activated in this model. Prior to inflammatory demyelinating lesions in the 
optic nerve, retinal deterioration with early RGC loss has also been observed (Hobom et al., 2004; 
Fairless et al., 2012).   
The aim of this study is to address questions regarding early RGC loss and axonal damage.  In AON, 
axonal loss was detected following BBB disruption and infiltration of inflammatory cells in the optic 
nerve parenchyma accompanied by demyelination. This primary axonal injury can retrogradely 
induce secondary RGC death which could explain retinal pathology following inflammation of the 
optic nerve. However, early RGC loss and ultrastructural axonal changes were observed prior to optic 
nerve pathology and these might initiate axonal injury prior to inflammatory driven demyelination 
(Fairless et al., 2012). These early changes are timed with increases in retinal Ca2+ and activation of 
the Ca2+-activated protease, calpain (Hoffmann et al., 2013). Since calpain is known to target 
structural components involved in axonal transport and the maintenance of cytoskeletal integrity, we 
wish to determine whether such changes occur and how they might fit into the Ca2+-activated 
cascades potentially involved in RGC degeneration. To address this, the following questions will be 
investigated: 
1) are axonal transport deficits detectable  during AON in optic nerves?  
2) is the mechanism of glutamate excitotoxicity involved in early RGC loss and cytoskeleton 
changes? 
3) is there a change in the expression of channels involved in Ca2+ homeostasis?   
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3 Methods 
3.1 Animals 
Female BN rats (8 - 10 weeks old; 140 – 160 g) were used in all EAE experiments. Sprague Dawley 
(SD) rat pups at postnatal day seven or eight (P7 - 8) were used for in vitro experiments for primary 
RGC cultures. All animals were purchased from Charles River (Sulzfeld, Germany) and kept under 
environmentally controlled pathogen-free conditions with free access to food and water. Animal 
experiments were performed according to the relevant laws and institutional guidelines of Baden-
Württemburg. 
 
3.2 MOG-EAE induction and animal scoring 
BN rats were immunised with whole recombinant rat MOG (a kind gift of Prof Christine Stadelmann, 
Dept. of Neuropathology, University of Göttingen; Fairless et al., 2012). Immunization emulsion 
contained 1:1 ratio of 100 µg MOG in phosphate-buffered saline (PBS, Sigma-Aldrich, St. Louis,  
Missouri, USA) and complete Freund’s adjuvant (Sigma-Aldrich) containing 200 µg of heat-inactivated 
Mycobacterium tuberculosis H37RA (Difco Microbiology, Lawrence, Kansas, USA). Rats were 
anaesthetized with 5% isoflurane inhalation and injected intradermally at the tail with 200 µl of 
immunization emulsion. Rats were observed daily for clinical signs of EAE. The grading system used 
to score neurological symptoms is presented in Table 3.2. 
Immunized animals were kept until the desired time point in the induction (iAON) or clinical (cAON) 
stage of the disease course. Animals with signs of severe ataxia or having a score of 3.5 or greater 
were sacrificed. 
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score clinical symptoms 
0.5 distal tail paresis 
1 complete tail paralysis 
1.5 
complete tail paresis and mild hind leg 
paresis 
2 unilateral severe hind leg paresis 
2.5 bilateral severe hind limb paresis 
3 complete bilateral hind limb paralysis 
3.5 
complete bilateral hind limb paralysis and 
paresis of one front limb 
4 
complete paralysis (tetraplegia), moribund 
state, or death 
 
Table 3.2 Grading scale of neurological symptoms in BN MOG-EAE. 
 
3.3 Retina excitotoxicity model – IVI of glutamate 
In order to induce a primary retinal insult, healthy BN rats received IVI of glutamate. During 
injections, animals were kept under anaesthesia by inhalation of 5% isoflurane. In total 100 nmoles 
of glutamate (4 µl of 25 mM glutamate (Sigma-Aldrich) in saline) was injected intravitreally using a 
patch pipette attached via a plastic tube filled with saline to a 10 µl Hamilton syringe over the course 
of 5 minutes. 24 hours following IVI of glutamate, animals were sacrificed by ketamine/xylazine 
overdose. Retina and optic nerves were further processed dependent on experimental design. 
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3.4 IVI of cholera toxin subunit B-Alexa Fluor 488 conjugate  
In order to investigate axonal transport deficits during the course of AON, an IVI of 4 µl of 0.1% 
Cholera Toxin subunit B conjugated to Alexa Fluor 488 (CTB – A488; Molecular Probes, Thermo Fisher 
Scientific Inc., Waltham, Massachusetts, USA) in sterile PBS was performed. 24 hours following the 
injection, animals were sacrificed by ketamine/xylazine overdose, perfused, and retinas with 
attached optic nerves were dissected and processed for longitudinal sections. 
 
3.5 Isolation and culture of primary RGC 
To investigate the physiology of RGCs independent of other retinal cells, a modified primary RGC 
isolation procedure was established. Our approach consisted of combining two previously reported 
techniques: MACS RGC isolation kit (MACS Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and 
panning protocol (Barres at al., 1989). The first part of the protocol - removal of negative cells with 
MACS RGC isolation kit gave a very low yield of RGCs and was replaced with a negative panning 
protocol as described in Barres et al. The second part of the protocol, positive selection for RGCs was 
performed with a MACS RGC isolation kit according to their instructions. For each preparation, five to 
seven SD pups P7-8 were decapitated, eyes were removed and retinae dissected followed by brief 
storage in room temperature (RT) Earle's balanced salt solution with Ca2+ and Mg2+ (EBSS; Gibco, 
Carlsbad, California, USA). The protocol is summarized below: 
1) Retina digestion and panning preparation 
For tissue digestion, EBSS was removed and papain mix was added to collected retinas for 10-15 
minutes at 37°C. Following digestion, the tube was centrifuged for 1-2 minutes at 1000g, the papain 
mix was completely removed and cells were re-suspended in 4 ml LoOvo mix. After 2 minutes 
centrifugation at 1000g, LoOvo mix was removed and cells re-suspended in a further 6 ml of LoOvo 
mix with added anti-rat macrophage antibody (1:75, Wak – chemie Medical GmbH, Germany) and 
incubated for 10 minutes at RT. Following centrifugation for 5 minutes (1000g; RT), cells were re-
suspended in 10 ml panning buffer for the negative panning selection procedure.  
 Papain mix consisted of 10 ml pre-heated Dulbecco's phosphate-buffered saline (DPBS, 
Sigma-Aldrich) rewarmed to 37°C with 165 Units of papain (Cellsystems GmbH, Troisdorf, 
Germany). Following heating to ease mixing, 2 μg L-cysteine (Sigma-Aldrich) was added to 
activate papain. Afterwards, the papain mix was filtered through 0.45 μm filters (Merck 
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Millipore, Billerica, Massachusetts, United States) and 100 μl DNase (10000 U/ml in EBSS; 
Sigma-Aldrich) was added. 
 LoOvo mixture consisted of 10% LoOvo stock in DPBS. LoOvo stock consisted of 1.5% bovine 
serum albumin BSA (Sigma-Alrich) with 1.5% ovomucoid (a trypsin inhibitor; Roche Holding 
AG, Basel, Switzerland) adjusted to pH 7.4. 
 Panning buffer consisted of 0.04% BSA in DPBS with 1% insulin (from bovine pancreas, 0.5 
mg/ml; Sigma-Aldrich). 
2) Negative selection with panning protocol 
Preparation of panning plates: Two Petri dishes (150 mm diameter; Corning Falcon, Tewksbury, USA) 
were incubated overnight, each with 20 ml 50 mM Tris – HCl (Sigma-Aldrich), pH 9.5, containing anti-
rabbit IgG (H+L) antibody (1:400, Dianova GmbH, Hamburg, Germany). The next day, before tissue 
collection, antibody was removed and 20 ml of 0.2% BSA in DPBS was added to each of the panning 
plates and left at RT. 
Following tissue preparation, 0.2% BSA was removed from both panning plates. Cells in 10 ml of 
panning buffer were filtered through a 30 μm cell strainer (Miltenyi Biotec GmbH), followed by 
incubation on the first panning plate for  30 minutes at RT, with gentle shaking of the plate every 10 
minutes. Following incubation, after which most of the unwanted microglia/macrophage cells were 
attached to the bottom of the dish, the cell suspension was filtered again through a 30 μm cell 
strainer and poured on the second subtraction plate for another 20 minutes at RT. Following this 
step, the cell suspension was again collected from the subtraction plate and filtered for the last time 
through a 30 μm cell strainer and centrifuged for 10 minutes (1000g; RT).  
3) Positive selection of RGCs with MACS RGC isolation kit 
Shortly, following centrifugation, cells were incubated with CD90.1 antibody attached to magnetic 
MACS beads in 5% DPBS. Positive selection was done following manufacturer’s instructions (Rat 
retinal ganglion cell isolation kit; Miltenyi Biotec GmbH).  
Following centrifugation for 5 minutes at 1000 g, supernatant was discarded and the pellet 
containing RGCs was re-suspended in RGC medium (RGM). Cell number was determined using a 
haemocytometer, before seeding cells on PLL-coated glass coverslips (VWR, Radnor, Pennsylvania, 
USA). Cells were seeded on ø 13 mm in 24 well plates or ø 25 mm in 35 mm dishes, depending on 
experiment design, and maintained in RGM. 
 Sato’s medium consisted of Neurobasal medium (Gibco) supplemented with 0.2% holo-
Transferrin human (Sigma-Aldrich), 0.2% BSA (Sigma-Aldrich), 0.025% progesterone (2.48 
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mg/ml (ethanol); Sigma-Aldrich), 0.016% putrescine, 1% sodium-selenite (0.4 mg/ml 
(Neurobasal medium); Sigma-Aldrich). 
 RGM consisted of Neurobasal medium (Gibco) supplemented with 1% Sato’s medium, 1% 
insulin (form bovine pancreas, 0.5 mg/ml; Sigma), 1% Na-pyruvate (100 mM; Sigma), 2% L-
glutamine (2 mM; Sigma-Aldrich), 1% Pen-Strep (10,000 U/mL; Gibco), 1% triiodothyronine 
(T3, 15nM; Sigma-Aldrich), 0.1% N-acetyl-L-cysteine (3 mg/ml; Sigma, USA), 2% B27 (B27 
Supplement x 50; Gibco), 0.1% ciliary neurotrophic factor (CNTF, 10 μg/ml; PeproTech Inc., 
USA), 0.1% brain derived neurotrophic factor (BDNF, 50 μg/ml; Tebu-bio GmbH, Germany), 
0.1% forskolin (10 mM; Sigma). In some experiments, 1:1 media mix of Neurobasal and 
Dulbecco’s modified Eagle’s medium (DMEM; GIbco) was used to obtain 290-300 mOsm 
osmolarity. If Neurobasal medium alone was used, sucrose was added to obtain the desired 
osmolality. RGCs were kept for two to four days in vitro (DIV 2 - 4) before they were used in 
different experiments. To check the viability of RGCs under in vitro conditions, some cultures 
were kept for up to three weeks. In some experiments, acutely isolated RGCs were needed. 
In this case, RGCs were processed immediately after the isolation. 
RGCs were also isolated from adult BN rats with different disease duration. In this case, the isolation 
method was the same as for pups RGC isolation, except for the following changes: all reagents were 
scaled down since only 2 animals were used per preparation; negative panning selection was done in 
smaller Petri dishes (100 mm diameter; Corning Falcon); and the amount of CD90.1 antibody used for 
positive selection was decreased appropriately (1:2, compared to the original protocol). In these 
experiments, RGCs were used acutely, in order to not lose their disease phenotype and because RGCs 
isolated from adult animals do not recover under in vitro conditions as well as RGCs isolated from P7-
8 pups. 
 
3.6 Tissue collection and processing 
3.6.1 Retinal whole-mounts 
For investigating numbers of RGCs an antibody against the RNA-binding protein with multiple splicing 
(Rbpms; Abcam PLC, Cambridge) was used, a relatively novel RGC marker (Rodriguez et al., 2014). 24 
hours following IVI of glutamate or at certain time points during EAE, BN rats were euthanized by 
inhalation of 5% isoflurane followed by decapitation and removal of the whole eyes from the eye 
sockets. Following dissection, vitreous body and pigment epithelia removal, retinas were mounted 
on nitrocellulose membranes (Membrane Filter Black, white grid; GE Healthcare Life Sciences 
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WatmanTM, Chicago, Illinois, USA) with the RGC layer uppermost. Following tissue mounting, retinal 
whole-mounts were immediately processed for antibody labeling (see Section 3.8).  
3.6.2 Preparation of frozen tissue sections 
At relevant time points during the disease course, animals were sacrificed by overdose i.p. injection 
of 20% ketamine (1.2 ml/kg) and 2% xylazine (0.6 ml/kg) and perfused via the aorta with 4% 
paraformaldehyde (PFA). Eyes still connected to the optic nerves were dissected and kept overnight 
in 4% PFA for additional tissue fixation and washed in PBS. After 12 hours in PBS, tissue was 
transferred into 30% sucrose (Applichem GmbH, Darmstadt, Germany) in PBS overnight for 
dehydration and cryoprotection. On the next day, tissue was put into plastic base moulds containing 
Cryoblock embedding medium (Medite, Burgdorf, Germany) and frozen using cold isopentane (Acros 
Organics BVBA, Geel, Belgium), cooled with liquid nitrogen. Frozen blocks were kept at -80°C prior to 
cutting. Four or eight µm thick longitudinal and 0.5 μm cross sections were cut using a cryostat 
(Leica, Wetzlar, Germany) at -20°C. Sections were transferred to SuperFrost® Plus microscope slides 
(Thermo Scientific, Waltham, Massachusetts, USA) and kept at -20°C prior to staining. 
 
3.7 Histopathology  
3.7.1 Luxol Fast Blue  
To illustrate the presence and extent of demyelination, 4 and 8 μm frozen longitudinal ON sections 
were stained with Luxol Fast Blue (LFB). Pre-cut samples were taken from -20°C and kept at RT to 
thaw and dry. Following defrosting, slides were rehydrated by washing them three times for 5 
minutes in PBS. Afterwards, they were incubated overnight in 0.1% LFB solution (Solvent blue 38, 
Sigma-Aldrich) at 60°C. The next day slides were cooled to RT and put in 90% alcohol. Each slide was 
put individually into 0.05% lithium carbonate solution (Sigma-Aldrich) until the colour of the tissue 
changed to turquoise, put in 70% ethanol and rinsed in tap water. Afterwards, the slides were put in 
periodic acid (Sigma-Aldrich) for 10 minutes followed by 5 minutes in running tap water. The slides 
were then incubated for 30 minutes in Schiff´s reagent (Sigma-Aldrich) and left under running tap 
water for 5 minutes for the blue colour to develop. In a final step, slides were counterstained with 
haematoxylin, dehydrated and mounted with Roti® - Histokitt II (Carl Roth, Karlsruhe, Germany). 
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3.7.2 Bielschowsky´s Silver Impregnation 
To determine the extent of axonal loss ON longitudinal sections were stained with Bielschowsky´s 
silver impregnation. Sections were thawed and rehydrated and afterwards incubated in 20% silver 
nitrate solution (Carl Roth) for 20 mins. Slides were then transferred to distilled water (dH2O). 
Ammonia (VWR) was added dropwise to the silver nitrate solution until it became clear. The slides 
were then transferred in the clear solution for 20 mins in the dark. Afterwards the developer was 
added dropwise until the tissue became brown. The stain was fixed with 2% sodium-thiosulfate 
(Sigma-Aldrich) for 2 mins. Finally, the sections were dehydrated and mounted with Roti® - Histokitt 
II. 
 
3.8 Immunofluorescent staining – general protocol 
Microscope slides with tissue were taken from -20°C and kept at RT to thaw and dry. Sections were 
rehydrated by washing three times for 5 minutes in PBS (referred to further in text as a washing 
step). Antigen retrieval if needed was done by heat – induced using 0.2% citrate buffer at pH 6.0 
previously preheated to around 90°C. Slides were immersed in boiling buffer and kept until the 
temperature dropped to 70°C. This was performed two times and the third time slides were kept in 
the buffer until it cooled down to RT. Afterwards the washing step was repeated. Nonspecific 
antibody binding was prevented by incubation of slides in blocking buffer (containing 10% normal 
goat/rabbit serum in 0.1% PBS Tween 20, PBS-Tw) for 1 hour at RT. Appropriate primary antibody 
was diluted in the blocking buffer and slides were incubated overnight at 4°C. The next day, after a 
washing step, slides were incubated with appropriate secondary antibody conjugated with 
fluorescent dye for 1 hour at RT. After final washing, slides were mounted with anti-fade Vectashield 
Mounting Medium (Vector laboratories, Burlingame, California, USA) with or without 4', 6-diamidino-
2-phenylindole (DAPI; cell nuclei visualization) and covered with glass cover slips. A detailed list of 
the blocking buffers, primary and secondary antibodies used are given in Table 3.8.1 and Table 3.8.2.  
For double immunofluorescence staining, two differently raised primary antibodies were used (eg. 
mouse and rabbit). Slides were incubated simultaneously with a mix of two different primaries and, 
subsequently, the mixture of appropriate secondary antibodies conjugated with different 
fluorophores. 
For all immunostaining procedures, appropriate negative controls were used where the primary 
antibody was omitted.   
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Fluorescent microscopy and image acquisition was performed using either a conventional Eclipse 80i 
microscope (Nikon; Shinagawa, Tokyo, Japan) or a LSM 700 confocal microscope (Zeiss).  
 
 
Antibody Company Sub-type Dilution Blocking buffer 
Antigen 
retrieval 
Neurofilament 
light (NFL) 
Millipore, 
Billerica, 
Massachusetts, 
USA 
Rabbit  
polyclonal 
1:500 
10% NGS/ 0.1% 
TBS-Tw 
Citrate buffer pH 
6.0 
Myelin basic 
protein  
(MBP) 
Sigma-Aldrich 
Rabbit  
polyclonal 
1:300 
10% NGS/ 0.1% 
TBS-Tw 
Citrate buffer pH 
6.0 
Kinesin (KIN) 
Chemicon 
International Inc., 
USA  
Mouse 
monoclonal 
1:800 
10% NGS/ 0.1% 
TBS-Tw 
Citrate buffer pH 
6.0 
Alzheimer 
Precursor 
Protein A4, a.a. 
66-81 of APP 
(βAPP) 
Millipore, 
Billerica, 
Massachusetts, 
USA 
Mouse 
monoclonal 
1:1000 
10% NGS/ 0.1% 
TBS-Tw 
Citrate buffer pH 
6.0 
Synaptophysin 
(SYN) 
Millipore, 
Billerica, 
Massachusetts, 
USA 
Mouse 
monoclonal 
1:800 
10% NGS/ 0.1% 
TBS-Tw 
Citrate buffer pH 
6.0 
RNA-binding 
protein with 
multiple 
splicing 
(Rbpms) 
Abcam, 
Cambridge, 
Great Britain 
Mouse  
polyclonal 
1:500 
10% NGS/ 0.3% 
TBS-Tr 
- 
Brain-specific 
homeobox/POU 
domain protein 
3A  
(Brn3a) 
Abcam, 
Cambridge, 
Great Britain 
Rabbit  
monoclonal 
1:200 
10% NGS/ 0.3% 
TBS-Tr 
- 
Anti-
Neurofilament 
Marker 
(SMI312) 
Covance 
Mouse IgG1 
cocktail 
1:1000 
10% NGS/ 0.3% 
TBS-Tr 
- 
Sodium-calcium 
exchanger 1 
(NCX1) 
Swant, 
Switzerland 
Rabbit 
 polyclonal 
1:200 
10% NGS/ 0.3% 
TBS-Tr 
- 
 
Table 3.8.1 List of primary antibodies used for immunofluorescent staining.  
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Antibody Company Sub-type Conjugate Dilution 
Goat anti-mouse 
Jackson 
labs/Dianova, West 
Grove, 
Pennsylvania, USA 
IgG Cy3 1:400 
Goat anti-mouse Invitrogen IgG Alexa 488 1:400 
Goat anti-rabbit 
Jackson 
labs/Dianova 
IgG Cy3 1:400 
Goat anti-rabbit Invitrogen IgG Alexa 488 1:400 
Rabbit anti-goat Invitrogen IgG Alexa 488 1:400 
Goat anti-rat Vector laboratories IgG Biotin 1:200 
 
Table 3.8.2 List of secondary antibodies used for immunofluorescent staining. 
 
3.8.1 Immunocytochemistry 
Previously isolated cells in culture, seeded on 13 mm covers slips in 24 well plates, had culture 
medium removed prior to careful washing with ice cold PBS. Cells were then fixed with 4% PFA for 10 
minutes and washed with 0.02% PBS-Tween 20 (PBS-Tw; Sigma-Aldrich). Cell permeabilization was 
performed with different detergents depending on the antigen of interest. For staining of 
cytoplasmic antigens, cells were treated with 0.1% PBS-Tw for 10 mins at RT whereas for the 
detection of nuclear antigens 0.1% PBS-Triton X-100 (PBS-Tr) was used. Following permeabilization 
and washing step, nonspecific binding was blocked by incubation with 10% NGS in 0.1% PBS-Tw for 
30 minutes at RT. Following blocking, cells were incubated overnight at 4˚C with the appropriate 
primary antibody diluted in blocking buffer. The next day, following washing step, cells were 
incubated with a fluorescent conjugated secondary antibody for 1 hour at RT. After final washing, 
coverslips were mounted on glass slides with mounting medium containing DAPI. 
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3.8.2 Immunofluorescent staining retinal whole–mounts 
Immediately after mounting retinas on nitrocellulose membranes in PBS, they were fixed with ice 
cold 4% PFA for 10 minutes and afterwards washed in PBS. For the purpose of improving penetration 
of the primary antibody, permeabilization was performed with 0.3% PBS-Tr for 10 minutes at RT. 
Following blocking for 1 hour at RT (blocking buffer contained 10% NGS in 0.3% PBS-Tr.), retinas were 
incubated overnight at 4˚C with the Rbpms primary antibody (1:500) in blocking buffer. The next day, 
following washing, retinas were incubated with Alexa – 488 conjugated secondary antibody for 1 
hour at RT. After final washing, retinas were mounted on glass slides with mounting medium 
containing DAPI. To determine RGC cell densities, four different areas were taken from each of four 
retinal segments. These areas were aligned longitudinally, from optic nerve head to the outer retinal 
rim, and pictures were taken using a conventional Eclipse 80i microscope (Nikon) at 20 x 
magnification, as shown in Figure 3.8.3.1. ImageJ free software (https://imagej.nih.gov/ij/) was used 
to quantify RGC density in each of the sixteen chosen areas. Using an implemented grid function, 
eight 0.01 mm2 squares were used per area (avoiding blood vessels) and in each square RGCs were 
counted using an ImageJ cell counting plug-in. All retinal whole-mounts were quantified in a blinded 
manner. The final result represented the RGC cell density per mm2 for an individual retina, as 
averaged across the whole retinal whole-mount.  
 
 
 
 
 
 
Figure 3.8.3.1 Graphical representation of retinal whole-mount. Green dots represent Rbpms
+
 RGCs. 
Red squares represent the positioning of areas of each retina used for RGC quantification.  
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3.9 Terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) assay 
A commonly used technique for the labelling of apoptotic cells is the TUNEL assay. This method 
involves the identification of fragmented DNA through covalent addition of labelled deoxyuridine 
triphosphate (dUTP) by the enzyme deoxynucleotidyl transferase (TdT; Gavrieli et al., 1992). This 
assay was performed on frozen optic nerve sections. After rehydration in PBS, sections were treated 
with proteinase K (20 μg/ml; Roche) for 5 mins at RT. Endogenous peroxidases were inactivated with 
3% H2O2 followed by rinsing in Tris buffer (10 mM Tris-HCl, pH 8.0; Carl Roth). Sections were 
equilibrated in TUNEL dilution buffer (TDB; Roche) for 10 mins at RT. The TUNEL reaction was 
performed in TDB containing TdT (0.15 U/μl; Promega, Madison, Wisconsin, USA) and biotin-16-dUTP 
(10 μM; Roche) for 60 min at 37°C. A positive control was performed by pre-treating sections with 
DNase I (3 U/ml; Roche) and a negative control was performed by omitting biotin-16-dUTP from the 
TUNEL reaction. The reaction was terminated by washing sections in saline sodium citrate solution 
(30 mM Na3C6H5O7 containing 300 mM NaCl; both from Sigma-Aldrich) for 15 mins. After rinsing in 
PBS, non-specific binding sites were blocked with 2% BSA-PBS for 20 mins at RT. Sections were then 
rinsed in PBS and incubated with the same blocking solution containing streptavidin–Alexafluor 488 
or 555 conjugate (1:700; Molecular Probes/Thermo Fisher) for 30 mins at 37 °C. After rinsing with 
PBS, sections were mounted using anti-fade mounting medium containing DAPI for visualisation of 
cell nuclei and quantified under the Nikon Eclipse 80i microscope with 20 x magnifications. 
 
3.10 Preparation of tissue lysates 
At desired time points during the course of EAE or 24 hours following IVI of glutamate, rats were 
sacrificed by decapitation after inhalation of 5% isoflurane. Optic nerves were dissected and 
mechanically homogenized in a glass homogenizer (Kontes, Vineland, New Jersey, USA) with ice cold 
lysis buffer containing cOmplete Protease Inhibitor Cocktail® (Roche, Mannheim, Germany). To 
further disrupt the integrity of the tissue, lysates were sonicated for 5 seconds. Cell debris was 
pelleted at 13000 rpm at 4°C for 15 minutes. Supernatants were collected and kept at -80°C prior to 
use.  
The total protein concentration in the sample was determined using a bicinchoninic acid (BCA) assay 
(Pierce, Rockford, Illinois, USA) following the instructions provided by the manufacturer. 
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3.10.1 Western blotting 
The expression of different proteins during the course of the disease was examined by Western 
blotting. Lysates containing 30 µg of total protein was diluted in 2x sample buffer (Anamed 
Elektrophorese, Groß-Bieberau, Germany) and incubated at 95°C for 10 minutes. Samples were 
loaded onto a 4–20 % gradient Mini-PROTEAN® TGX Stain-Free™ Precast gels (BioRad, Hercules, 
California, USA). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) for 1 hour and 20 mins at 120 V in a running buffer containing 25 mM 
Tris Base (Carl Roth), 190 mM glycine (Sigma) and 0.1% SDS (Carl Roth). Following electrophoresis, 
the semi-dry blotting technique using Trans-Blot® Turbo™ Transfer System (BioRad) was used for 
protein transfer to a polyvinylidene difluoride (PVDF) membrane (BioRad). Different blotting settings 
(provided by the transfer system) were utilized depending on the molecular weight of the protein 
investigated. The membrane was incubated in blocking buffer containing 5% milk (Skim milk powder; 
Sigma) or 5% BSA in 0.1% TBS-Tw, depending on the antibody used, for 1 hour at RT. Following the 
blocking step, the membrane was incubated in the same blocking buffer with addition of the 
appropriate primary antibody overnight at 4°C. On the following day, the membrane was washed in 
TBS-Tw and incubated with the corresponding HRP-conjugated secondary antibody for 1 hour at RT. 
A list of different blocking agents and primary/secondary antibodies is given in Table 3.10.1. 
Following the washing step, the membrane was incubated with the ECL Prime reagent (Amersham, 
USA) for one minute and imaged using the ChemiDoc™ XRS+ Imaging System (BioRad). 
The expression of the protein of interest in the sample was normalized to the expression of the 
house-keeping protein Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Millipore). A minimum 
of 3 samples per time point were used in the final quantification for each protein. Quantification of 
the results was performed using ImageJ free software with the implemented plug-in for Western blot 
quantification. 
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Protein 
 
Company 
Blocking buffer 
Primary antibody 
dilution 
Secondary antibody 
Fractin 
 
Millipore, Billerica, 
Massachusetts, 
USA 
5% milk 0.1% TBS-T 1:1000 
Donkey anti-rabbit 
HRP-conjugated, 
1:5000 
Gelsolin 
 
Abcam, 
Cambridge, 
Great Britain 
5% milk 0.1% TBS-T 1:1000 
Donkey anti-goat 
HRP-conjugated, 
1:5000 
GAPDH 
 
Millipore, Billerica, 
Massachusetts, 
USA 
5% milk 0.1% TBS-T 1:2500 
Sheep anti-mouse HRP-
conjugated, 1:5000 
 
Table 3.10.1. Combination of different blocking agents and primary/secondary antibodies for Western 
blotting. All secondary antibodies were purchased from Amersham (Buckinghamshire, GB). 
 
3.10.2 Globular versus filamentous actin ratio assay 
Actin network dynamics were evaluated during the course of disease using the globular versus 
filamentous actin ratio assay (G/F-actin ratio) on optic nerve lysates. Tissue preparation and protocol 
was followed to detail as given in the manual of G-actin / F-actin In Vivo assay kit (Cat. #BK037; 
Cytoskeleton Inc., Denver, Colorado, USA). Briefly, optic nerve lysates were collected in F-
stabilization buffer and ultra-centrifuged at 100,000g, 37°C for 1h. In all the experiments, an Optima 
Max – E ultracentrifuge (Beckmann Coulter Inc., Brea, California, USA) with TLA – 55 FixedAngleRotor 
(Beckmann Coulter) was used and samples were prepared in 1.5 ml ultracentrifuge tubes 
(Microfuge® Tube Pollyallomer; Beckmann Coulter). Following ultra-centrifugation, supernatant was 
carefully removed (G-actin fraction) while the pellet was re-suspended in F-actin depolymerizing 
buffer (F-actin fraction). Following sample preparation, the protocol for Western blotting was 
identical to the one used for normal tissue lysates. G/F-actin ratio was calculated as the ratio of 
globular versus filamentous actin band intensity using the ImageJ application for Western blot 
quantification. 
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3.11 Live dead assay 
To evaluate the quality of primary RGC cultures and cytotoxic effects of 24 hour glutamate 
treatment, ethidium homodimer 1 (EthD-1) was used (Molecular Probes, Thermo Fisher Scientific) 
was used. EthD-1 is a high-affinity nucleic acid stain that is weakly fluorescent until bound to DNA 
and emits red fluorescence.  It cannot cross the intact plasma membrane of live cells. Briefly, media 
was carefully removed from cultured RGCs (~5.000 cells seeded on 13 mm coverslips) before washing 
with PBS. Cells were then incubated in 0.5 μm EthD-1 in PBS (250 µl) for 15 minutes at RT. 
Afterwards, coverslips were mounted without washing on glass slides with mounting medium 
containing DAPI and immediately examined on a conventional Eclipse 80i microscope (Nikon). Cells 
were imaged with 20x magnification and six different areas of interest were taken (four on the outer 
rim and two in the centre of seeded cells) and counted using ImageJ free software with a cell 
counting plug-in. Results were expressed as the percentage of healthy cells (detected by the absence 
of EthD-1+ labelling and round DAPI positive nuclei) compared to the total counted cells (live and 
dead together) in all experimental settings. 
 
3.12 Ca2+ imaging 
Ca2+ dynamics of RGCs after glutamate receptor stimulation was addressed using ratio-metric Fura-2 
(Molecular Probes, Life Technologies) Ca2+-imaging. RGCs, seeded on 25 mm diameter glass 
coverslips (~5.000 cells per cover slip), were incubated with 5 ng/μl of Fura-2 (1 μg/ul in DMSO; 
Molecular Probes, Life Technologies) in RGM for 20 minutes on 37°C. Following incubation, cells were 
washed in basic Fura-2 imaging solution (FIS; Table 3.10.1) for 5 minutes and transferred to an 
imaging chamber (Attofluor® Cell Chamber; Molecular Probes, Invitrogen) with the appropriate 
imaging solution (Table 3.9.1). Cells were recorded using the Nikon Total Internal Reflection 
Fluorescence (TIRF) microscope but in wide-field epifluorescence mode. A helium lamp with 
excitation filters for 340 and 380 nm wavelengths and an emission filter of around 510 nm was used 
for illumination, and data was recorded using a Hamamatsu Ocra AG camera (Model C4742-80-
12AG). Ten to thirty cells were captured in the field of view imaged with a 20x objective (Nikon S 
Fluor 20x NA 0.75 (working distance 1.0 mm), corrected for 0.17 mm coverslips (= type #1.5)). A 
Nikon Perfect Focus System (PFS3) was included, that continuously determined the distance to the 
coverslip, readjusting it if required, for instance because of thermal drift. For live cell imaging, the 
system was equipped with an on-stage incubation chamber (TokaiHit) for controlling the 
temperature, CO2 concentration and humidity. Care was taken during the imaging process to prevent 
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bleaching and photo-toxicity by choosing the shortest possible excitation times (200/60 ms for 
340/380 nm wavelengths) and the least frequent data sampling rate (every 2 seconds in short 5 – 10 
minutes experiments; every 30 seconds in 1-1.30 hour experiments). 
Treatment experiments were performed by adding 300 µl of amount of imaging solution (10 mM 
HEPES, 5 mM glucose, 120mM NaCl, 2.8 mM KCl, 3mM CaCl2x2H20, 20.4 mM sucrose) with different 
stimulators or blockers (Figure 3.12). This large addition volume allowed rapid distribution of the 
added compounds.  All additions were performed by hand using a 1 ml pipette, with care taken to 
not cause any additional pressure on the cells that might affect Ca2+ dynamics).  
The fluorescence images were converted into ratio-metric (340/380 nm) data with imaging software 
Nikon NIS 4.13. Briefly, region of interests (ROIs) around each cell body were automatically selected, 
corrected for the background signal and processed further for 340/380 nm ratio values.  
All Ca2+ imaging experiments were performed at the Nikon Imaging Center Heidelberg (http://nic.uni-
hd.de/). 
 
 
 
 
 
Figure 3.12 Graphical representation of RGC Fura-2 ratio-metric Ca2+ imaging. Green dots 
represent RGCs on a 25 mm glass coverslip mounted in the imaging chamber.  
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3.13 Quantitative Real Time - Polymerase Chain Reaction (qRT-PCR)  
Total RNA was isolated from RGCs of adult BN rats and P7-8 pups SD rats using an RNAeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Total amount of RNA and 
dsDNA was measured on Qubit®2.0 fluorometer (Thermo Fisher Scientific) with Qubit®2.0 RNA Assay 
Kit and Qubit®2.0 dsDNA HS Assay Kit (Thermo Fisher Scientific). To generate the desired cDNA pool 
from RNA templates, Transcriptor high fidelity cDNA synthesis kit (Roche, Germany) was used. qRT-
PCR was performed on an ABI 7000 thermal cycler with SYBR Green PCR Mastermix (Applied 
Biosystems, Waltham, Massachusetts, USA). All samples were analysed in duplicate. All primers used 
in the qPCR experiments were designed using online NCBI Primer BLAST tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi; Table 3.11) and whenever possible separated by at least one 
intron on the genomic DNA to exclude amplification of genomic DNA. PCR reaction products were 
controlled by including no-RT-controls, by omission of templates and by melting curve analysis. The 
analyses of relative gene expression data gene was determined using the 2−[ΔΔCt] method by 
comparison of threshold values, normalized to a house-keeping gene, in this case glyceraldehydes-3-
phosphate dehydrogenase (GAPDH). 
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Rat Genes NCBI Reference qPCR primers 
Sodium Calcium Exchanger 1 
(NCX 1) 
Kuroda et al., 2013. F:GTGTTTGTCGCTCTTGGAACCTC 
R: CGTTGCTTCCGGTGACATTG 
Sodium Calcium Exchanger 2 
(NCX 2) 
NM_078619.1 F: TGGAGGGAGCAGTTTTTAGA 
R: CATCACGTAGTCAAAGCAGG 
Sodium Calcium Exchanger 3 
(NCX 3) 
NM_078620.2 F: CTGGAAGCTAAGGGGAATCG 
R: CTCTGCTCGAAGACCATTCA 
Calcium ATPase 1 
(PMCA 1) 
NM_053311.1 F: AGGTGTGGAGAAGAAGGGA 
R: GCCCATGACTTGTTTCTTCC 
Calcium ATPase 2 
(PMCA 2) 
NM_012508.5 F: CACCATCTCACTGGCCTATT 
R: CTTGTAGTGGACATCACCGA 
Calcium ATPase 3 
(PMCA 3) 
NM_133288.1 F: GCTCCATGACGTAACCAATC 
R: TACGGAATGCTTTCACCACT 
Glutamate ionotropic receptor 
AMPA type subunit 1 
(Gria 1) 
NM_031608.1 F: ACTCAAGCGTCCAGAATAGG 
R: CCACACAGTAGCCCTCATAG 
Glutamate ionotropic receptor 
AMPA type subunit 2 
(Gria 2) 
NM_001083811.1 F: GGTACGACAAAGGAGAGTGC 
R: TTTGCCACCTTCATTCGTTT 
Glutamate ionotropic receptor 
AMPA type subunit 4 
(Gria 4) 
NM_001113184.1 F:TACGACAAAGGAGAATGTGGCA 
R: GCCGCCAACCAGAATGTAG 
Glutamate ionotropic receptor 
NMDA subtype 1 
(Grin 1) 
NM_001270602.1 F: GCGTCTGGTTTGAGATGATG 
R: ATAGGACAGTTGGTCGAGGT 
Glutamate ionotropic receptor 
NMDA subtype 2a 
(Grin 2a) 
NM_012573.3 F: AGTGGTCTATCAACGAGCAG 
R: TGATTCCTGTCTCCACGAAG 
 
Glutamate ionotropic receptor 
NMDA subtype 2b 
(Grin 2b) 
NM_012574.1 F: CAGCATTCCTACGACACCTT 
R: ATGAATCGGCCCTTGTCTTT 
 
Calcium voltage – gated 
channel subunit alpha -1A 
(Cacna 1A) 
NM_012918.3 F: CACCGAGTTTGGGAATAACT 
R: AAAGTCCAGAGGAGAATGCG 
Calcium voltage – gated 
channel subunit alpha -1C 
(Cacna 1C) 
NM_012517.2 F: GATTGTTGTGGGTAGCATTGT 
R: GGGAGAGCATTGGGTATGTT  
Calcium voltage – gated 
channel subunit alpha -1B 
(Cacna 1B) 
NM_001195199.1 F: GGTGGCATTTGCATTCTCAG 
R: CAGTCAAACACAGCCTTGAG 
 
glyceraldehydes – 3 – 
phosphate dehydrogenase 
(GAPDH) 
NM_017008.4 F: CAGGGCTGCCTTCTCTTGTG 
R: TGGTGATGGGTTTCCCGTTG 
 
 
 
 
Table 3.13 Primers used for qRT-PCR analyses. NCBI reference number is added next to the self-
designed primer pairs using NCBI primer BLAST tool. 
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3.14 MK801 and SEA0400 treatment studies during iAON 
In order to investigate the role of NMDA activation during iAON on RGC loss and actin axonal 
network changes,  MOG-immunized animals received IVI of 4 nmoles MK801 (4 μl of 1mM MK801-
maleate (Sigma-Aldrich) diluted in sterile-filtered saline) on day 4 and again on day 7 post-
immunization (day 4 p.i. and day 7 p.i.). Control animals received the corresponding IVI of 4 μl saline. 
In order to investigate the role of NCX1 in early RGC loss and actin axonal cytoskeleton changes, the 
NCX reverse-mode blocker SEA0400 (ApexBio; Houston, Texas, USA) was used. EAE animals received 
IVI of 4 nmoles SEA0400 (4 μl of 1mM SEA0400) in 1% DMSO in sterile-filtered saline) on day 4 p.i. 
and day 7 p.i. Control animals received the corresponding IVI of 4 μl 1% DMSO in saline. Following 
both treatments, retinas were further prepared for whole-mounting followed by Rbpms-staining to 
determine RGC cell density, and optic nerves were used for the G/F-actin assay. 
 
3.15 Statistical analyses 
All data are presented as their mean values ± standard error of the mean (SEM). All data analyses 
were done using SigmaPlot 12.5 software. Where two experimental groups were compared, if data 
were normally distributed (as assessed by the Shapiro-Wilk test), statistical significance was assessed 
by two-tailed Student’s t-test. If data failed the Shapiro-Wilk test, statistical significance was assessed 
by Mann-Whitney rank sum test. Where more than two groups were compared in normally 
distributed data (as assessed by the Shapiro-Wilk test), one way analysis of variance (ANOVA) 
combined with post hoc Dunnett's method was used for comparing multiple experimental groups 
versus controls. If data failed the Shapiro-Wilk test, Kruskal-Wallis one way analysis of variance on 
ranks followed by Dunn's method was used for comparing multiple experimental groups versus 
controls. Three levels of significance were defined: * p value ≤ 0.05 was considered significant, ** p 
value ≤ 0.01 was considered strongly significant; *** p value ≤ 0.001 was considered highly 
significant. 
 
 
 
 
R e s u l t s     42 
4 Results 
4.1 Disease course 
Following immunization with MOG, rats were scored daily for the appearance of neurological EAE 
deficits – see Methods, chapter 3.2). The average day of onset of EAE was between days 12 and 14 
post immunization (p.i.; n = 24; Figure 4.1.A), with symptoms appearing as early as day 11 p.i.. 
Simultaneously with the onset of EAE, identified by the development of neurological symptoms 
indicative of spinal cord lesions, animals develop autoimmune optic neuritis (AON) with high 
incidence. AON is typically characterised histopathologically by the presence of inflammatory 
demyelinating lesions in the optic nerves accompanied by axonal loss (Fairless et al., 2012; Figure 
4.1.B). 
 
 
 
 
 
 
 
Figure 4.1. Time-course of MOG-EAE and AON. (A) Neurological score of rats following immunisation with 
MOG, as assessed by clinical spinal cord deficits typical of EAE. The timing of clinical EAE onset correlates 
strongly with the onset of autoimmune optic neuritis (AON; Fairless et al., 2012); and thus the pre-clinical 
phase is considered as the induction phase of AON (iAON), and the period of neurological deficit is 
considered the clinical phase of AON (cAON). Average onset of cAON is on day 12 post immunazation (n = 
24 animals). (B) Representative images showing demyelination (LFB) and axonal loss (Bielschowsky) in the 
optic nerve in cAON phase, illustrating that the histopathological hallmarks of AON correlate with the 
disease stages identified by EAE clinical impairment. Scale bars 100 µm.  
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4.2 Early RGC loss detection with the anti-Rbpms immunostaining of 
retinal whole-mounts 
RGC loss was previously shown to start during the iAON in BN rats by retrograde labelling with 
Fluorogold (Fairless at al., 2012.). This finding was re-evaluated in this study using 
immunofluorescent staining of retinal whole-mounts with an antibody against Rbpms, a novel 
selective marker for RGCs (Rodriguez et al., 2014). For the purposes of this study, RGC cell densities 
in healthy versus day 10 p.i. (late stage of iAON) animals were compared (Figure 4.2.A). In healthy 
animals, the average number of Rbpms-positive RGCs per mm2 (2391 ± 45) was significantly higher 
compared to that in iAON animals (2191 ± 32, p = 0.0003; Figure 4.2.B).  
 
 
 
 
 
4.3 Axonal transport deficits during AON 
Previous studies of neurodegeneration in AON have hinted at the potential for an axonal transport 
deficit during the induction disease phase due to the identification of calpain-mediated degradation 
of spectrin within the optic nerve (Hoffmann et al., 2013), and also disturbances in the ultrastructural 
integrity of optic nerve axons (Fairless et al., 2012). In order to address potential axonal transport 
deficits during AON, immunofluorescence staining was performed against different proteins involved 
in the machinery of transportation: anterograde transport “motor” protein - kinesin (kin), synaptic 
vesicle “cargo” protein - synaptophysin (syn) and the axonal stress and transport failure marker - 
beta-amyloid precursor protein (βAPP). Co-staining with myelin basic protein marker (MBP) was used 
Figure 4.2. Anti-Rbpms staining confirming early RGC loss during iAON. (A) Representative retinal whole-
mounts stained with Rpbms antibody in healthy and iAON animals. (B) RGC cell density is significantly 
decreased in retinas during iAON compared to healthy retinas (n = 3 healthy animals, 6 retinas; n = 4 iAON 
animals, 8 retinas; *** p ≤ 0.001, Student’s t-test). 
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to check the myelination status of axons and, together with cell nuclei labelling with DAPI, aided the 
identification of inflammatory demyelinating lesions. Specificity of accumulated transport proteins 
within RGC axons was confirmed with double staining against neurofilament light protein (NFL). 
4.3.1 Axonal transport profile in the ONH 
The ONH is the area where RGC axons are naturally unmyelinated (Figure 4.3.1), and has been 
suggested to be an area of potential vulnerability to injuries such as glaucoma (Chidlow et al., 2008; 
Cherecheanu et al., 2013) and AON (Fairless et al., 2012). For instance, during iAON the ONH was the 
area of the optic nerve with the greatest microglial activation (Fairless et al., 2012). Thus, the 
identification of axonal transport deficits might be more apparent within this potentially vulnerable 
area. In addition, although a previous investigation of APP in the optic nerve did not identify any 
areas of accumulation prior to cAON onset (Fairless et al., 2012), this was performed only on cross 
sections from the distal optic nerve, and thus could have missed key areas. Following 
immunostaining for axonal transport protein accumulation, clusters of immunoreactivity could be 
seen in cAON (Figure 4.3.1.1.C.i-iii; Figure 4.3.1.2.C.i-iii), where it correlated with regions of cellular 
density indicated by DAPI labelling, demonstrating areas of inflammatory infiltration. However, 
accumulation of axonal transport proteins within the ONH was not observed during iAON (Figure 
4.3.1.1.B.i-iii; Figure 4.3.1.2.B.i-iii). 
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Figure 4.3.1.1 Axonal transport deficits in the ONH are observed with the onset of cAON. ONH could be 
identified as the unmyelinated retro-bulbar region of the optic nerve, as seen with MBP staining (green). 
Accumulation of axonal transport proteins (Kin (A-C.i), βAPP (A-C.ii), Syn (A-C.iii); red) was visible with the 
appearance of hyper-cellularity due to infiltration of immune cells, as indicated by DAPI staining (blue), in the 
proximal optic nerve part. Bottom row represents enlarged areas marked with yellow rectangles in panel 
above (C.i-iii; n = 6 animals per time point investigated; scale bars 100 µm, insert 10 µm).  
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4.3.2 Axonal transport profile in the distal optic nerve 
In parallel with the ONH, more distal regions of the optic nerve where RGC axons are fully myelinated 
(Figure 4.3.2.1) were also investigated for evidence of axonal transport protein accumulation. As was 
seen in the ONH, during cAON there was evidence of transport protein accumulation (Figure 
4.3.2.1.C.i-iii; Figure 4.3.2.2.C.i-iii), but this was not seen during iAON. Interestingly, accumulation of 
βAPP was present within and in the vicinity of inflammatory demyelinated lesions, in both 
myelinated and demyelinated axons on optic nerve cross-sections (Figure 4.3.2.3.A). The same was 
observed for the accumulation of Syn (Figure 4.3.2.3.B).  
Figure 4.3.1.2. Transport markers accumulate within RGC axons in the ONH with the onset of cAON. ONH 
axons are visualized using the anti-NFL antibody (green). Accumulation of transport proteins (Kin (A-C.i), 
βAPP (A-C.ii), Syn (A-C.iii); red) were localized to NFL labeled axons in the proximal optic nerve part. . Bottom 
row represents enlarged areas marked with yellow rectangles in panel above (C.i-iii; n = 6 animals per time 
point investigated; scale bars 100 µm, insert 10 µm).  
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Figure 4.3.2.1. Axonal transport deficits in the optic nerve are observed with the onset of cAON. (A) Distal part 
of the optic nerve consists of myelinated RGC axons, as seen with MBP staining (green). No accumulation of 
axonal transport proteins (Kin (A-C.i), βAPP (A-C.ii), Syn (A-C.iii); red) is visible prior the onset of inflammatory 
demyelination (areas of increased DAPI positive nuclei). Bottom row represents enlarged areas marked with 
yellow rectangles in panel above (C.i-iii; n = 6 per time point; scale bars 100 µm, insert 10 µm). 
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Figure 4.3.2.2. Transport markers accumulate within RGC axons in optic nerves with the onset of cAON. In the 
distal part of the optic nerve accumulation of axonal transport proteins (Kin (A-C.i), βAPP (A-C.ii), Syn (A-C.iii); 
red) localize to NFL positive axons (green) prior the onset of inflammatory demyelination (areas of increased 
DAPI positive nuclei). Bottom row represents enlarged areas marked with yellow rectangles in panel above (C.i-
iii; n = 6 per time point; scale bars 100 µm, insert 10 µm). 
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 Figure 4.3.2.3. Optic nerves cross-sections profile of transport proteins accumulation in cAON. (A)  βAPP 
(red) was visible in both myelinated (orange square insert, thick arrows) and unmyelinated (yellow square 
insert, open arrows) axons. (B) Syn (red) was visible in both myelinated (orange square insert, thick arrows) 
and demyelinated (yellow square insert, open arrows) axons following the onset of cAON (n = 3; scale bar 50 
μm). 
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4.3.3 Cholera Toxin B subunit A488-conjugate for detection of axonal 
transport deficits during AON   
In addition to determining areas of transport protein accumulation to identify axonal transport 
deficits, cholera toxin B-subunit (CTB), a common tracer used to map out axonal projections can also 
be used (Abbott et al., 2013). CTB conjugated to Alexa 488 was injected into the vitreous body of the 
eye, and left for 24 hours to be transported along the RGC axons in an anterograde direction. The 
ONH was then assessed for evidence of CTX-A488 accumulation. In the iAON ONH (Figure 4.3.3.A.i), 
the initial axonal projections were heavily labelled with CTX-A488, but this was not different in 
appearance to that of the healthy ONH (Figure 4.3.3.B.i). In contrast, during cAON, areas of CTXB-
A488 accumulation was seen in both the initial and distal regions of the optic nerve (Fig. 4.3.3.C.i-ii), 
where it correlated with the borders of infiltrated lesions (see Fig. 4.3.3.C.ii insert), representing 
regions of axonal damage where axons had not been totally lost. 
 
 
 
 
Figure 4.3.3. CTB-A488 accumulation is associated with inflammatory lesions following the onset of cAON. 
No change in labeling pattern of CTB-A488 was seen between healthy and iAON 24 hours following intravitreal 
injection of the tracer (A.i-ii; B.i-ii). After the onset of cAON, CTB-A488 was detected within inflammatory 
lesions (C.ii). Insert shows an inflammatory lesion co-stained with DAPI (n = 3 per time point; scale bars 100 
µm, insert 10 µm).  
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4.4 Actin network profile in optic nerves during AON 
4.4.1 G/F-actin ratio is increased along the course of AON 
The actin network has been shown to be both a sensor and a mediator in the process of apoptotic 
cell death (Desouza et al., 2012; Franklin-Tong & Gourlay, 2008). Knowing that RGC loss during AON 
was confirmed to be mostly of apoptotic nature (Fairless et al., 2012) accompanied by retinal and 
optic nerve Ca2+ increases (Hoffmann et al., 2013), the status of the RGC axonal actin network was 
next addressed. This was achieved using a sedimentation assay allowing the ratio of globular to 
fibrous actin to be assessed (the G/F-actin ratio). This ratio was significantly elevated already during 
iAON (0.88 ± 0.20) when compared to healthy animals (Figure 4.4.1; 0.38 ± 0.09, p = 0.04). The same 
was observed in animals at the onset of cAON (1.20 ± 0.22, p = 0.011 compared to the healthy 
animals).     
 
 
 
 
 
Figure 4.4.1. Actin network disassembly during AON. The G/F-actin ratio increases in the optic nerve 
during disease progression. This increase in ratio is detectible starting from the iAON (* p < 0.05, one 
way ANOVA with post hoc Dunnett’s multiple comparison test; n = 4 animals per time point). 
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4.4.2 Expression of proteins associated with actin cytoskeleton changes 
during AON 
Considering that changes in the actin network were observed during AON in the optic nerve, the 
expression of proteins implicated in actin network dynamics that are affected in the process of 
apoptosis by caspases, gelsolin (a mediator of F-actin disassembly)  and fractin (a G-actin monomer 
cleavage product), were investigated by Western blot. 
The expression of these proteins was found to be changed during AON.  There was a statistically 
significant decrease of gelsolin levels in both iAON (0.55 ± 0.05, p = 0.014) and cAON (0.34 ± 0.06, p < 
0.001) when compared to healthy animals (0.77 ± 0.07, Figure 4.4.2.A).  Conversely, there was a 
significant accumulation of the G-actin cleaved product fractin in optic nerves from both iAON (0.48 ± 
0.07, p = 0.012) and cAON (0.64 ± 0.09, p < 0.001), when compared to healthy animals (0.17 ± 0.04; 
Figure 4.4.2.B). 
 
 
 
 
4.5 Intravitreal injection of glutamate as a model of primary RGC 
loss 
Intravitreal injection (IVI) of excessive levels of different glutamate receptor agonists has long been 
known to induce the loss of RGCs and their axons in the optic nerve (Luo et al., 2001; Chidlow et al., 
2008). The phenomenon of glutamate excitotoxicity is suspected to play a role in the animal model of 
AON since 
Figure 4.4.2. F-actin severing protein gelsolin and G-actin are both affected during AON. (A) Gelsolin 
levels decrease during AON. (B) Fractin levels are increased during AON. (* p < 0.05; *** p ≤ 0.001, 
ANOVA with post hoc Dunnett’s multiple comparison test; n = 6 animals per time point). 
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 the initial RGC loss correlates with increased Ca2+ levels in the retina (Hoffmann et al., 2013). In 
addition, minocycline treatment was shown to reduce retinal glutamate levels during iAON (Maier et 
al., 2007). In order to examine this hypothesis, naive BN rats following IVI  with 100 nmoles of 
glutamate were examined 24 hours later to determine if it resulted in optic nerve and retina 
alterations similar to those observed during AON.  
 
4.5.1 RGC loss following IVI of glutamate 
Anti-Rbpms immunostaining was used in order to quantify the density of surviving RGCs following 
the injection of glutamate (Figure 4.5.1.A). The density of RGCs in glutamate-injected retinas (1931 ± 
75 RGC per mm2) was found to be significantly decreased compared to control animals receiving IVI 
of saline (2217 ± 54 RGC per mm2, p = 0.013). In addition, RGC loss was confirmed by TUNEL assay 
(Figure 4.5.1.B). TUNEL+ cells were also found in other retinal layers (inner and outer nuclear layers) 
similar to what was observed in retinas from animals with AON (Fairless et al., 2012). 
 
 
 
Figure 4.5.1. Intravitreal glutamate injection leads to RGC loss. (A) Retinal whole-mount stained with the 
Rpbms antibody 24h following intravitreal injection of saline or glutamate. In the glutamate injected retinas, 
RGC numbers were significantly reduced compared to the saline injected (n = 4 animals / 8 retinas; * p < 
0.05, Student t-test). (B) TUNEL
+
 cells were found only in retinas of animals that received the IVI of 
glutamate (white arrows point at TUNEL positive cells in ganglion cell layer-GCL; inner nuclear layer-INL; 
outer nuclear layer-ONL). 
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4.5.2 Axonal transport profile following IVI of glutamate 
Immunofluorescent staining of optic nerve sections was performed in order to investigate whether 
IVI of glutamate would cause the failure of axonal transport. The accumulation of proteins involved 
in axonal transport (Kin, Syn, βAPP), which would be indicative of its failure, was not observed 24 
hours following IVI of glutamate neither in the ONH (Figure 4.5.2.A), nor in the distal segment of the 
optic nerve (Figure 4.5.2.B). 
 
 
 
Figure 4.5.2.  Axonal transport deficits are not detected 24 hours following IVI of glutamate. No visible 
accumulation of axonal transport proteins (Kin (A-B.i), βAPP (A-B.ii), Syn (A-B.iii); red)was detected 24 
hours following intravitreal injection of glutamate in the ONH (A) or along the optic nerve (B) (n = 3 per 
time point). 
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4.5.3 G/F-actin ratio is increased in optic nerves following IVI of glutamate  
G/F-actin assay was used in order to investigate whether IVI of glutamate affects the actin 
cytoskeleton in a similar way to that observed in AON. The G/F-actin ratio was found to be 
significantly increased in animals injected with glutamate (1.75 ± 0.47, p = 0.011; Figure 4.5.3) when 
compared to saline injection (0.53 ± 0.08). Again, this was similar to that observed in animals with 
AON, compared to healthy ones (Figure 4.4.1). 
 
 
 
 
 
4.6 Blockade of the NMDA receptor protects RGCs and reverses 
actin network changes in the optic nerve during iAON 
In order to confirm if NMDA glutamate receptors are involved in early RGC loss and changes in the 
optic nerve actin network during iAON, IVI of NMDA-receptor blocker MK801 (dizocilpine) was 
performed. MK801 was chosen since it is a use-dependent and prolonged blocker that exerts stable 
effects for some time after the drug has been washed out (Huettner & Bean, 1988; McKay et al., 
Figure 4.5.3. IVI of glutamate affects the organization of the optic nerve actin network. An increase in 
the G/F-actin ratio is detectible in optic nerves 24 hours following the IVI of glutamate (n = 3, *p ≤ 0.05, 
compared to saline injected animals, Student’s t-test).  
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2013). Since the G/F actin ratio was altered during iAON in a similar way to IVI of glutamate, the next 
question was whether glutamate receptor blockade would therefore reduce these observed 
alterations. Previously, it was shown that systemic application of MK801 was neuroprotective during 
AON (Sühs et al., 2014). However, this neuroprotective effect in the retina may have been observed 
because of the overall change in EAE progression after systemic blocker application. In this study, IVI 
of MK801 was applied in order to affect only AON progression and therefore reduce retinal 
deterioration. Animals received IVI of MK801 twice during iAON: at day 4 p.i., a day prior to the 
earliest reported RGC loss (Fairless et al., 2012) and repeated at day 7 p.i. to ensure prolonged 
blocker effect. Animals were sacrificed at late stage iAON, day 10 p.i.. The density of surviving RGCs 
was significantly elevated in the MK801 treatment group (2331 ± 34 RGC per mm2, p = 0.0005) 
compared to the control saline group (2136 ±27 RGC per mm2, Figure 4.6.1.A) during iAON. 
G/F-actin assay was used in combination with MK801 treatment. Following IVI of MK801, the G/F-
actin ratio was significantly decreased (0.25 ± 0.04, p = 0.016), compared to the saline injected 
animals (0.82 ± 0.17). In addition to restoring the G/F-actin ratio to values found in healthy optic 
nerves (Fig. 4.4.1), MK801 treatment during iAON also led to changes in the expressional changes in 
both gelsolin and fractin in optic nerves. Gelsolin levels in MK801-treated animals were significantly 
increased (0.70 ± 0.04) compared to saline-treated animals (0.43 ± 0.03, p = 0.0005) during iAON. 
Levels of fractin were significantly decreased following IVI of MK801 (0.12 ± 0.03) when compared to 
saline-injected animals (0.32 ± 0.03, p = 0.002).  
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Figure 4.6.  IVI of MK801 in the early phase of iAON is neuroprotective. (A) The density of RGCs is 
significantly increased following MK801 treatment compared to the control saline group during iAON (n 
= 4 animals /8 retinas per group; *** p < 0.001, Student t-test). (B) The G/F-actin ratio is decreased 
following IVI of MK801 when compared to saline-injected animals (n = 6 animals per group, *p < 0.05, 
Student t-test). MK801 treatment leads to a significant increase of gelsolin (C) and a decrease of fractin 
(D) in the optic nerve when compared to control animals (n = 5 for saline and n = 4 animals for MK801 
treatment, ** p ≤ 0.01, *** p < 0.001, Student’s t-test). 
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4.7 mRNA expression of Ca2+-permeable channels in RGC is 
regulated during the course of AON 
The treatment with NMDA receptor blockers (see previous chapter) as well as previous works 
(Gadjanski et al., 2009; Hoffmann et al., 2013; Sühs et al., 2014) highlighted the importance of Ca2+ 
dynamics in the pathophysiology of AON. Taking this into consideration, qRT-PCR on acutely isolated 
RGCs (two hours following euthanasia of animals, thus representing physiology of RGCs at the time of 
isolation) was used in order to investigate whether channels involved in Ca2+ dynamics are 
differentially expressed during AON. NCX1 and PMCA3 were found to be significantly up-regulated 
during iAON while the L-type VGCC, and subunits of the NMDA (Grin2b) and AMPA (GluR1) receptors 
were up-regulated during cAON (Table 4.7). 
 
 Table 4.7. Screening of Ca2+ related channel expression in RGCs acutely isolated at different time 
points during AON. Data were analyzed with the 2−[ΔΔCt] method, with GAPDH as the internal control 
(n = 6 for healthy and iAON; n = 5 for cAON). The values presented in the table are coefficients with 10
-3
 
base. The expression of channels during iAON and cAON was compared to healthy values using the one 
way ANOVA with post hoc Dunnett’s multiple comparison test (NCX1, Cacna1c, Grin2b, GluR1) and 
Kruskal-Wallis test on ranks followed by Dunn’s multiple comparison test (PMCA3). 
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4.8 Utilization of primary RGC cultures for studying Ca2+ responses 
following glutamate stimulation 
The primary RGC culture was used as an in vitro model to study Ca2+ dynamics following glutamate 
receptor stimulation. The culture conditions used in this study were established previously by Barres 
et al., 1998. RGC medium (RGM, see chapter 3.5) includes BDNF, CNTF and forskolin previously 
described to provide best conditions for RGC viability (Meyer-Franke et al., 1995). However, the 
presence of growth factors might interfere with glutamate-induced neuronal excitotoxicity (Melo et 
al., 2013).In this study, we first tested if it would be possible to take them out of the RGM. In the case 
they were kept in RGM, RGCs underwent neurite extension within two weeks, as observed with 
immunostaining for pan-axonal marker (SMI312; Figure 4.8.A). In the case BDNF, CNTF and forskolin 
were omitted from the medium, cells viability was significantly decreased after two days in vitro (56 ± 
1%) compared to the cells kept in RGM (45 ± 3%, p = 0.03; Figure 4.8.B). This decline in cell viability 
without BDNF, CNTF and forskolin  in RGM progressed further after four days in vitro (55 ± 3%) 
compared to the cells in RGM (27 ± 3, p = 0.002; Figure 4.8.C). Considering this, RGM was used for 
cultivation of primary RGCs in all experiments. 
 
 
 
Figure 4.8. RGC viability is dependent on BDNF, CNTF and forskolin. (A) Examples of RGC differentiation 
at different time points in the RGM. This was true only in the case RGCs were kept in RGM. Live dead assay 
on isolated RGCs in different medium conditions after two (B) and four (C) days in vitro was significantly 
decreased (RGM: full mediumRGM-FBC: full medium without forskolin, BDNF and CNTF; n = 4, * p < 0.05, 
** p ≤ 0.01, DIV2-Mann-Whitney Rank Sum Test, DIV4-Student’s t-test). 
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4.8.1 Primary RGC culture is not prone to glutamate excitotoxicity  
Glutamate excitotoxicity is one of the proposed mechanisms of neurodegeneration in the retina 
under different pathological conditions (see chapter 1.9.2). The question of glutamate excitotoxicity 
in cultivated RGCs has been controversial since previously published works gave conflicting results 
with regard to whether RGCs were susceptible to glutamate excitotoxicity in culture (Ullian et al., 
2004; Hartwick et al., 2008). In order to investigate the viability of primary RGC culture following 
prolonged exposure to toxic levels of glutamate, a cell toxicity assay was performed using EthD1 
labelling. Cells were exposed to 100 µM glutamate and 10 µM glycine (NMDA receptor co-agonist) in 
RGM over the course of 24 hours (Figure 4.8.1.A). There was no significant difference observed 
between the numbers of healthy RGCs in the control versus the glutamate-treated group (Figure 
4.8.2.B).  
 
 
 
 
 
4.8.2 Ca2+ dynamics in primary RGCs following glutamate receptor stimulation 
In order to investigate Ca2+ dynamics following glutamate receptor stimulation of primary RGCs, 
ratio-metric Fura-2 Ca2+ imaging was used. Glutamate receptors were stimulated by addition of 
different agonists in the imaging solution: glutamate and glycine, NMDA or AMPA. In control 
experiments, only imaging solution was added (Figure 4.8.2.A). Agonist application induced an initial 
Ca2+ response, which was greatest for co-application of glutamate and glycine, followed by NMDA, 
and then AMPA (Fig. 4.8.2.B.iii). This is expected since glutamate stimulates both NMDA and AMPA 
Figure 4.8.1. RGC invulnerability to glutamate excitotoxicity. (A) Cell toxicity assessment of isolated RGCs 
in control conditions (left) and 24 hours following glutamate exposure (right). Dying cells are labeled with 
EthD-1 (red) and have shrunken nuclei. (B) The percentage of dead cells compared to the total cells 
counted (number of DAPI-positive cells – both healthy and shrunken) was not changed following RGC 
exposure to glutamate (n = 6 experiments; Student’s t-test). 
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receptors and NMDA receptors have a greater permeability coefficient for Ca2+ than AMPA receptors 
(Traynelis et al., 2010). Cells were then maintained for between 1 and 1.5 hours in order to observe 
the phenomenon of delayed calcium deregulation (DCD), considered to be an essential factor leading 
to cell death (Budd & Nicholls, 1996; Tymianski et al., 1993). Only a few cells underwent DCD (Figure 
4.8.2.A, traces in red) irrespective of the agonist they were exposed to (glutamate and glycine 4.2%, 
n = 5/119; NMDA 0.85%, n = 3/352; AMPA 1%, n = 2/216). Interestingly, this was also observed under 
control conditions (6%, n = 5/85).  
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4.8.3 Role of NCX in Ca2+ dynamics following glutamate stimulation of RGCs 
The role of NCX in Ca2+ intracellular extrusion/influx following glutamate receptors stimulation has 
been already addressed in several studies on isolated CNS neurons (Bano et al., 2005; Araujo et al., 
2007), but so far not on isolated RGCs. NCX1 channel expression on RGCs was observed with 
immunocytochemistry (Figure 4.8.3.1.A). In addition, mRNA levels of NCX1 were increased in 
cultured RGCs (Figure 4.8.3.1.B), as well as in RGCs isolated from iAON (Table 4.7). NCX essentially 
has two modes of action: in physiological conditions it is assumed to work predominantly in forward -
mode, extruding Ca2+ from the cell together with PMCA. However, in the conditions of high 
intracellular Na+ levels, it may act to bring more toxic Ca2+ into the cell (Stys et al., 1997). In order to 
test if NCX contributes to intracellular Ca2+ increase following glutamate receptor stimulation the 
NCX reverse-mode blocker SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline) 
was used. This blocker is considered to be the most potent and specific NCX reverse-mode blocker 
with a high specificity for the NCX1 isoform (Matsuda et al., 2001).  
The effect of SEA0400 on Ca2+-dynamics following glutamate-glycine stimulation was investigated 
using ratio-metric Fura-2 Ca2+ imaging (Figure 4.8.3.2). In control experiments, only the imaging 
solution was added at the second and fifth minute into recording (n = 190 cells). After beginning of 
recording, cells were either pre-treated with/without NCX blocker (10 nM, n = 216; 100 nM n = 196; 
1 μM, n = 148) 3 minutes prior to addition of glutamate-glycine (Fig 4.8.3.2.A). Application of 
different concentrations of SEA0400 alone to the imaging solution did not affect basal Ca2+ levels on 
isolated RGCs (Figure 4.8.4.B.i). However, once glutamate-glycine stimulation was applied, 
immediately (Figure 4.8.4.B.ii., red circles) and a few minutes later (Figure 4.8.4.B.ii, black diamonds), 
Ca2+ levels were significantly lower if cells were pre-treated with SEA0400. In both cases the 
magnitude of the Ca2+ decrease was found to be dependent on the concentration of SEA0400 (Figure 
4.8.4.B.ii). 
 
Figure 4.8.2. RGC Ca
2+
 dynamics following glutamate receptor stimulation. (A) Ca
2+
 dynamics of isolated 
RGCs after treatment with different glutamate receptor agonists (addition 5 mins into recording) over 
70-90 min. Ca
2+
 traces of individual RGCs are shown in grey, except for those that later underwent DCD, 
which are shown in red. The blue line represents the average response of RGCs not undergoing DCD (B.i) 
Scheme representing time points at which individual traces were used for quantification in B.ii-iv. (B.ii) 
Baseline Ca
2+
 levels were equivalent prior to agonist stimulation in all four experimental groups. (B.iii)  
Ca
2+
 increase was the highest in RGCs exposed to glutamate and glycine. (B.iv) Prolonged glutamate 
receptor stimulation led to a significant increase in intracellular Ca
2+
 when compared to control non-
stimulated cells. Experimental groups were compared either to control or to glutamate-glycine treated 
group using Kruskal-Wallis test on ranks followed by Dunn’s multiple comparison test and Mann-
Whitney Rank Sum Test in the case only two groups were compared (n.s. - not significant, *** p < 0.001). 
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Figure 4.8.3.1 NCX1 expression on P7-8 isolated RGCs. (A) NCX1 staining of isolated RGCs following one 
(DIV1) and three days (DIV3) in culture. (B) qRT-PCR of NCX isoforms expression were analyzed with the 
2−[ΔΔCt] method, with GAPDH as the internal control (n = 3). The values presented in the table are 
coefficients with 10
-3
 base. The expression of NCX in acutely isolated and RGCs in culture after three days 
were compared using the one way ANOVA with post hoc Dunnett’s multiple comparison test. 
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Figure 4.8.3.2 SEA0400 reduces the Ca
2+
 increase following glutamate receptor stimulation of isolated 
RGCs. (A) Representative example traces of control experiments (blue); glutamate-glycine stimulation 
(green); SEA0400 blocker application prior to glutamate-glycine addition (purple). Rectangles represent 
time points at which individual traces were used for quantification. (B.i) Baseline Ca
2+
 levels were not 
changed following SEA0400 addition into the imaging solution. (B.ii) The increase of Ca
2+
 following 
glutamate-glycine addition (5
th
 minute into recording) was dependent on concentration of SEA0400. Levels 
of Ca
2+
 recorded several minutes (8-9 mins) following glutamate-glycine addition were also dependent on 
the SEA0400 concentration present in the imaging solution. Levels of Ca
2+
 following glutamate-glycine 
stimulation is stable for 5 min following addition while they decrease when cells were pre-treated with 
SEA0400. Experimental groups were compared using Kruskal-Wallis test on ranks followed by Dunn’s 
multiple comparison test (n.s. - not significant, * p < 0.05, *** p < 0.001). 
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4.9 Treatment study with NCX1 receptor blocker SEA0400 in AON 
In chapter 4.6, a possible role for Ca2+ in the process of RGC loss in iAON was supported by the 
protective effect of MK801 application. It was therefore of interest to see whether NCX also played a 
role in the process of iAON-associated RGC degeneration, perhaps acting downstream of glutamate 
activation. In order to address this question, application of the NCX reverse-mode blocker SEA0400 in 
a disease setting was made.  
Intravitreal application of SEA0400 during the early iAON was performed in the same way as with the 
MK801 treatment: at day 4 p.i., a day prior to the earliest reported RGC loss (Fairless et al., 2012) and 
at day 7 p.i. to ensure prolonged blockade. Animals were sacrificed in late stage iAON, day 10 p.i.. IVI 
of SEA0400 did not show any protective effect on RGC survival in treated (2150 ± 23 RGC per mm2, 
Figure 4.9.A) versus control (2111 ± 32 RGC per mm2) animals. Similarly, in the optic nerve, the actin 
G/F-actin ratio in SEA0400-treated animals (1.2 ± 0.2, Figure 4.9.B) was not different compared to 
control saline-injected animals (1.5 ± 0.2). Similar results were observed following IVI of glutamate 
where co-application of SEA0400 had no effect (data not shown). 
 
 
 
Figure 4.9. SEA0400 treatment during iAON did not show neuroprotective effects during iAON. 
(A) The density of Rbpms+ RGCs was not significantly different in control compared to SEA0400-
treated animals (n = 6, n.s. - not significant; Student t-test). (B) Also, the optic nerve G/F-actin 
ratio remained unchanged irrespective of treatment with SEA0400 (n = 4 per, n.s. – not 
significant, Student’s t-test).  
D i s c u s s i o n     67 
5 Discussion 
5.1 Anti-Rbpms staining can be used for detection of RGC loss in 
iAON  
Retinal degeneration is connected with many ophthalmological and systemic neurodegenerative 
diseases including glaucoma, age-related macular degeneration, retinitis pigmentosa, cancer and 
autoimmune diseases, including MS (Balendra et al., 2015). In MS, ON is a common first sign of 
disease development (Balcer, 2006). The appearance of BBB disruption and inflammatory 
demyelinated lesions in the optic nerve is accompanied by retinal degeneration (Roed et al., 2005; 
Green et al., 2010; Syc et al., 2012; Kupersmith et al., 2016). However, changes in the retina, 
observed by ganglion and inner retinal layers have also been observed in the eyes of some MS 
patients irrespective of the presence of ON (Saidha et al., 2011; Walter et al., 2013). These findings, 
together with the detection of GM lesions in the cortex and axonal changes in the NAWM initiated 
the research of neurodegenerative processes in MS irrespective of primary demyelination (Haines et 
al., 2011).  
There is a variety of techniques available for the assessment of RGC loss in different experimental 
models. Genetically modified animals with fluorescently labelled RGC-specific markers, such as Thy1, 
can be used for the in vivo detection of retinal degeneration (Leung et al., 2008). Specific labelling of 
apoptotic RGCs can be performed with an annexin V-based method - Detection of Apoptotic Retinal 
Cells (DARC; Guo & Cordeiro, 2008) or with the use of a small cell-permeable caspase-activated 
imaging probe CapQ (Galvao et al., 2013). One of the most widely used methods is retrograde 
labeling of RGCs by the injection of lipophilic dyes into the superior colliculi. One of these dyes, 
Fluoro-gold, is assumed to label cells by crossing cell membranes in its uncharged form but ultimately 
is trapped within lysosomes and endosomes by a favourable pH gradient (Wessendorf, 1991). RGCs 
can also be quantified in retinal whole-mounts and sections with the use of RGC-specific antibodies, 
such as Brn3a (Nadal-Nicolás et al., 2012: Lanz et al., 2017) and Rbpms (Rodriguez et al, 2014) or with 
nonspecific, pan-neuronal antibodies such as NeuN (Wang et al., 2005; Dijk et al., 2007). 
However in different models of optic nerve and retinal injury, the extent of RGC loss can vary 
significantly depending on the technique used. The loss of RGCs might be over- or underestimated 
due to the specificity of the method used for labelling. For example, Fluoro-gold was shown to 
spread into amacrine cells (Abdel-Majid et al., 2005) and in the case of retinal injury even into 
microglia/macrophages via phagocytosis (Heiduschka et al., 2010; Mead et al., 2014). By counting 
only the number of cells in the ganglion cell layer, one can overestimate the number of RGCs, due to 
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the presence of displaced amacrine cells and astrocytes, which can comprise up to 50% of the total 
cell population in this layer (Perry, 1981; Mead & Tomarev, 2016). On the other side, several RGC-
specific antibodies can also lead to erroneous interpretations of RGC loss, since they only label a sub-
population of the RGCs - an issue that is commonly overlooked (Sanes & Masland, 2015). For 
example, Brn3a-specific labelling has been shown to underestimate RGC number in the rodent retina 
(Nadal-Nicolás et al., 2015).  
Fluoro-gold has been used previously in the BN-AON model where it was proven to be sensitive 
enough to detect the RGC loss in iAON (Hobom et al., 2004; Fairless et al., 2012). However, this 
method is time costly - animals need to be injected at least a week prior to MOG immunization to 
avoid any possible axonal retrograde transport deficits in the optic nerve that would affect vesicular 
tracer transport to the RGC bodies. Also the method itself is invasive – surgical procedure needs to 
be performed in order to inject the tracer into the areas of the brain that are targeted by RGC axonal 
projections (superior colliculi). Finally, RGC quantification needs to be performed soon following 
retinal removal because of the fast bleaching properties of Fluoro-gold. In this study, a relatively 
novel antibody against Rbpms was used to label RGCs. Rpbms as an RGC-specific marker was 
suggested a decade ago following a study on the gene expression profile of RGCs (Piri et al., 2006). It 
has been shown to be superior to Fluoro-gold since it does not label disperse amacrine cells and, is 
stable following injury unlike Brn3a (Rodriguez et al, 2014). 
In the present study, Rbpms staining was specific and sensitive enough to confirm RGC loss during 
iAON (Figure 4.2). The total density of RGCs per mm2 was decreased around 10% in iAON compared 
to healthy animals. In a previous study by our group using the same BN-AON model, it was reported 
that Fluoro-gold labelling revealed an RGC loss of about 20% at the same disease stage compared to  
healthy animals (Fairless et al, 2012). This discrepancy in RGC loss might come from differences in the 
total RGC number counted. In healthy animals, total RGC number per mm2 following Fluoro-gold 
labelling was reported to be 2046 ± 208 (Fairless et al., 2012) compared to the 2391 ± 45 cells per 
mm2 found in this study with anti-Rbpms antibody. Lower RGC loss in the case of Rbpms staining 
could be due to the fact that in this case all RGCs are counted, while in the case of Fluoro-gold only 
the populations of RGCs whose axons terminate in the superior colliculi are being quantified. It could 
be possible that within Fluoro-gold labelled RGCs there are sub-populations of cells that are 
particularly vulnerable to pathological signals during iAON. This would explain why in the case of 
Rbpms staining, when all RGCs are taken into account, the Fluoro-gold sub-populations contribute 
less in overall RGC count statistics. For example, following optic nerve crush it was observed that 
largest RGC types, alpha-RGCs (αRGCs), survive preferentially but not exclusively following such kind 
of injury (Duan et al., 2015). The other possibility might be that Fluoro-gold heavily labelled amacrine 
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cells as well, and that 10% higher increase in what is supposedly RGC loss comes from those retinal 
interneurons.   
 
5.2 Axonal transport deficits do not precede RGC loss during iAON  
One of the possible mechanisms that have been proposed to contribute to MS neurodegeneration is 
impairment of axonal transport (Lingor et al., 2012). Recent studies have shown that axonal transport 
deficits are observed following the onset of inflammatory demyelination in both optic nerves (Lin et 
al., 2014) and spinal cords (Sorbara et al., 2014) of EAE mice.  
The primary cause of early RGC loss in AON is currently still unknown. One of the proposed 
mechanisms could be axonal transport deficits as suggested in the model of glaucoma. In this model, 
axonal transport deficits were observed prior to RGC loss in the retina (Chidlow et al., 2011). In the 
ONH, RGC axons are naturally unmyelinated which makes them potentially more vulnerable to 
harmful influences. In our model, disruptions in the BBB in the ONH and BRB together with the 
activation of microglia in both compartments were observed during iAON (Fairless et al., 2012). It 
could be hypothesized that activated microglia might damage axons through production of ROS/RNS 
leading to mitochondrial damage and increased axonal Ca2+ (see chapter 1.5). Downstream of this 
Ca2+ increase, axonal transport deficits and axonal cytoskeleton network might then be disturbed, 
leading to and axonal swellings. 
In the present study, both the ONH and distal parts of the optic nerve were inspected for axonal 
transport defects during AON. Our hypothesis was that if the axons were damaged prior to RGC 
bodies, axonal transport accumulation would be visible due to normal protein production but 
obstructed within stressed axons, as was suggested in the animal model of glaucoma (Chidlow et al., 
2011). However, if the primary damage would be to the RGC bodies in the retina, this might impair 
protein production and thus have an invisible effect further downstream in the optic nerve axons. 
Accumulation of axonal transport markers was observed only after the onset of the cAON, in both 
the ONH (Figure 4.3.1.1-2) and in the distal optic nerve (Figure 4.3.2.1-3). Along the optic nerve, 
accumulation of transport proteins was detected only within areas of inflammatory lesions. This was 
also confirmed by similar observations following IVI of CTB-A488 (Figure 4.3.3), whose transport is 
known to be dependent on intact microtubules (Abbott et al., 2013). In the example cases of Syn and 
βAPP (Figure 4.3.2.3), protein accumulation was visible in both myelinated and demyelinated axons 
within inflammatory lesion. This implies that disruption of microtubule-associated transport might be 
an early event in axonal degeneration. Transport can be halted by inflammatory mediators (eg. 
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ROS/RNS), commonly found in high levels within inflammatory lesions, that could pass through the 
myelin barrier, damage mitochondria and initiate Focal Axonal Degeneration (Nikic et al., 2011). 
Following demyelination, transport deficits might be initiated due to axonal cytoskeleton 
restructuring (de Waegh & Brady 1990, Brady et al. 1999) and a lack of metabolic support by 
oligodendrocytes (Saab et al., 2013; Fünfschilling et al., 2016). This was confirmed in different 
genetically modified mouse strains lacking the major structural proteins of CNS myelin. These 
animals developed a late-onset, slowly progressing axonopathy and axon degeneration (Griffiths et 
al. 1998, Yin et al. 1998, Lappe-Siefke et al. 2003). 
Considering that deficits in axonal transport were not observed during iAON, even in the area of the 
ONH, they are presumably not the underlying cause of the early RGC loss. In addition, IVI of 
glutamate which leads to primary RGC loss did not cause any observable disturbances in axonal 
transport (Figure 4.5.2) and thus mirrored the observations obtained during iAON that primary RGC 
degeneration does not result in visible axonal transport deficits. 
It should be noted that the technique used in this study to characterize axonal transport 
(immunohistochemistry) also has limitations. Although care was taken to cover as much of the ON 
area as possible, it could be that some parts of the tissue were not examined. It might also be that in 
the iAON phase, axonal transport is not obstructed, but only slowed down or more frequently 
paused. Also another drawback of immunohistochemistry is that it provides a pathological image 
frozen in time which could pose a problem while studying highly dynamical processes such as axonal 
transport. In a recent study, mitochondria and peroxisomes were traced in vivo using two-photon 
imaging of EAE mice spinal cords (Sorbara et al., 2014). Persistent arrest of organelles was only seen 
within inflamed spinaI cords. However, in the NAWM, within totally preserved axons, transport of 
mitochondria was affected in another way. There was no permanent accumulation of these 
organelles, but the duration of stops was significantly increased, particularly in the retrograde 
direction. Although it was not discussed in that study, mitochondrial arrest could be connected with 
intra-axonal Ca2+ increases. Mitochondrial motility is decreased following a rise in axonal Ca2+ (Rintoul 
et al., 2003; Yi et al., 2004). This could also be the case in iAON where an increase in the optic nerve 
Ca2+ has been reported (Hoffmann et al., 2013). 
 
5.2 Actin cytoskeleton as a marker of axonal stress in AON 
Inflammatory-driven demyelination in ON is not present during the iAON disease phase (Figure 4.1; 
Fairless et al, 2012). However, examination of the optic nerve ultrastructure by electron microscopy 
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at this disease stage revealed shrunken axons and the appearance of vacuoles in the peri-axonal 
space despite normal-appearing myelin sheaths (Fairless et al., 2012). This indicated that there could 
be some axonal destruction prior to the demyelination process. In previous work of our group, it has 
already been shown that in iAON there is an increased level of the calpain-specific 147 kDa spectrin 
break-down product. Calpain activity correlated with the detection of increased Ca2+ levels within 
AON as detected by MEMRI (Hoffmann et al., 2013).  
Besides spectrin, the axonal sub-membrane cytoskeleton is composed of different adaptor proteins 
(ankyrins) and the actin network (Bennett & Gilligan, 1993). Since spectrin is an anchoring protein 
between plasma membrane channels and the axonal cytoskeleton via actin filaments, we wanted to 
address whether the actin network is also affected in iAON. The G/F-actin ratio in the optic nerve, 
providing information on the dynamics of the actin network, was observed to increase starting from 
iAON (Figure 4.4.1). This finding implies that axonal cytoskeleton re-organization precedes the axonal 
transport deficits that were detected later on during the cAON disease stage. The observed G/F-actin 
ratio could be the consequence of an upstream trigger of RGC apoptosis. This is supported by the 
evidence of the G/F-actin ratio increase following primary retinal insult, IVI of glutamate (Figure 
4.5.1-3). 
Since it was hypothesized that actin network restructuring might be due to Ca2+-dependent actin 
binding proteins, one of the villin family proteins, gelsolin was investigated. This protein has been 
reported to have an anti-apoptotic role following a rise of intracellular Ca2+, which might suggest that 
the observed G/F-actin ratio change might be a feed-back mechanism by which the axons are coping 
with the intra-axonal Ca2+ increase, presumably by modulating Ca2+-permeable plasma membrane 
channel activity (see chapter 1.11). When cells then enter the process of apoptotic death, gelsolin is 
cleaved by activated caspases. In this study it was observed that the 98 kDa (full protein) gelsolin 
levels decrease starting during iAON (Figure 4.4.2.A).  
 Another actin-remodeling phenomenon associated with apoptosis is caspase-3-induced cleavage of 
the actin G-monomer (see chapter 1.11). In our model, starting during iAON, fractin levels were 
significantly increased compared to healthy animals (Figure 4.4.2.B). Both the changes observed 
regarding gelsolin and fractin levels are in agreement with the previous report that the RGC loss 
which begins during iAON and progresses with the onset of cAON is apoptotic in nature (Fairless et 
al., 2012).  
In conclusion, the axonal actin network is affected early on during AON and, together with the 
spectrin cleavage previously observed, they may be the initiators of the axonal ultra-structural 
changes. Further on, these intra-axonal changes could be reflected in functional visual deficits and 
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disruptions of axo-myelin synapses at the Nodes of Ranvier where first irregularities have been 
observed during iAON (Aleksandar Stojic, PhD thesis 2016).  
 
5.4 NMDA glutamate receptor is involved in RGC 
neurodegeneration during iAON 
One of the neurodegenerative mechanisms assumed to be involved in MS pathology is glutamate 
excitotoxicity. In the context of neuro-inflammation, inflammatory cells are a potential source of 
extracellular glutamate through the cysteine/glutamate anti-porter Xc (Pampliega et al., 2011). 
Activated monocytes and microglia/macrophages have been reported to potentially be the main 
sources of glutamate in MS, based on findings from the EAE model (Evonuk et al., 2015). Glutamate 
released from monocytes might also activate glutamate receptors expressed on endothelial cells 
(Krizbai et al., 1998; Sharp et al., 2003; Andras et al.,2007), facilitating their infiltration and 
subsequent CNS inflammation. Altered glial glutamate uptake and release via glutamate transporters 
might also initiate synaptic glutamate increases in MS patients (Domercq et al., 2005; Werner et al., 
2001).  In axons, vesicular release of glutamate at the axo-myelinic synapse is also possible (Micu et 
al., 2016). Once extracellular glutamate is increased, overstimulation of metabotropic- and 
ionotropic-glutamate receptors might lead to prolonged Ca2+ increases and finally neuronal cell death 
(Dong et al., 2009). In EAE models, different glutamate receptors agonists have been shown to 
ameliorate EAE disease severity and progression: NMDA-receptor blockers, MK801 and memantine 
(Bolton & Paul, 1997; Sühs et al., 2014), and the AMPA-receptor blocker NBQX (Pitt et al., 2000; 
Smith et al., 2000), reduced neurological deficits and neurodegeneration. In BN-AON, there have 
been indications of the role of glutamate in retinal degeneration. Glutamate levels and RGC loss in 
the retina were ameliorated after systemic application of minocycline, already in iAON (Maier et al., 
2007).  
In this present study, IVI of glutamate was used in order to investigate the extent of injury that an 
increase in retinal glutamate could cause, to both RGC bodies and axons. Twenty four hours 
following IVI of glutamate, both RGC loss (Figure 4.5.1) and the G/F-actin ratio in the optic nerve 
(Figure 4.5.3) were of similar values as observed during the iAON disease stage. This change in actin 
network dynamics preceded any accumulation of axonal transport proteins, a sign of axonal 
transport deficit, or the appearance of axonal swellings (Figure 4.5.2). Similar observations have been 
made in a rat glaucoma model, where the axonal cytoskeleton within the retina, including F-actin, 
were disturbed before any RNFL thickness changes could be detected (Huang et al., 2011). 
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Recognizing that a glutamate-induced retinal insult results in the similar RGC loss and axonal 
responses as in iAON, a treatment study - blockade of retinal NMDA glutamate receptors (with 
MK801) during iAON - was performed. 
MK801 (dizocilpine) has been used in different applications - as an anticonvulsant (Wong et al., 
1986), an antipsychotic (Hunt et al., 2015) and a neuroprotector (Yoles et a., 1997; Berman & 
Murray, 1996). It is established that MK801 is a specific antagonist of the NMDA glutamate receptor 
that is effective once NMDA receptors are open (Huettner & Bean, 1988; Halliwell et al., 1989), i.e. it 
is use-dependent. It is considered to be a prolonged, irreversible blocker, though it has been shown 
that the blockade efficiency depends on channel activity and Mg2+ ion presence (McKay et al., 2013). 
The effect of MK801 treatment in iAON was visible in both retina and optic nerves. The density of 
RGCs in late iAON was significantly increased following IVI of MK801 compared to saline-injected 
control animals (Figure 4.6.A). In addition, the optic nerve G/F-actin ratio was significantly decreased 
in MK801-treated eyes (Figure 4.6.B), and correlated with the gelsolin increase (Figure 4.6.C) and 
fractin decrease (Figure 4.6.D) compared to control eyes.    
NMDA receptor stimulation following IVI of NMDA in the retina has been known to induce RGC loss 
(Munemasa et al., 2006; Bai et al., 2013; Sakamoto et al., 2010; Manabe & Lipton, 2003).  Molecular 
changes involved in retinal injury downstream of NMDA receptor stimulation in addition to direct 
Ca2+ influx through the NMDA receptor pore are diverse: activation of other Ca2+ permeable plasma 
membrane channels, e.g. VGCCs (Melena & Osborne, 2001), mobilization of intracellular Ca2+ stores 
(Lei et al., 1992), pro-apoptotic activation of c-Jun N-terminal kinase and p38 mitogen-activated 
protein kinase (Munemasa et al., 2005), activation of RhoA pathway (Kitaoke et al., 2004), etc. 
However, based on our previous report on calpain activity (Hoffmann et al., 2013), prolonged 
intracellular Ca2+ increase following NMDA receptor activity and Ca2+-mediated injury appears to be 
the relevant mechanism. In addition, it remains to be investigated to what extent the silencing of 
NMDA receptors expressed on RGCs alone contributes to their protection, particularly since MK801 
effect could also mediate more indirect effects. For example, it has been reported that increased 
extracellular glutamate affects BBB permeability via NMDA receptor stimulation (Sharp et al., 2003; 
Andras et al., 2007; Vazana et al., 2016). MK801 application might have reversed BRB induced 
damage by decreasing influx of fibrin (Davalos et al., 2012) or pro-inflammatory cytokines from T-
cells detected within the choroid in iAON (Fairless et al., 2012).  For example, MK801 might have also 
affected the BRB permeability (known to be disrupted in iAON; Fairless et al., 2012) by acting on 
endothelial NMDA receptors, and in that way reduced potential harmful blood components and 
cytokines leakage into the retina (Vazana et al., 2016; Kusaka et al., 1999).  
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5.3 Invulnerability of RGCs to glutamate excitotoxicity in vitro  
In order to investigate downstream mechanisms of glutamate-induced RGC loss, a primary RGC 
culture was established based on the protocol first described by Barres et al., 1998. The phenomenon 
of glutamate excitotoxicity was historically first reported in the retina (Lucas & Newhouse, 1957). 
Since then, it was observed in different neuronal populations throughout the CNS and is shown to be 
involved in the majority of neurodegenerative diseases (Lipton & Rosenberg, 1994). In vitro studies 
on different CNS neuronal populations, such as cortical (Chinopoulos et al., 2004), spinal (Tymianski 
et al. 1993) and cerebellar granule neurons (Bano et al. 2005), all confirmed glutamate-induced cell 
death in about 60 -80% of cells accompanied by the phenomenon of delayed Ca2+ deregulation 
(DCD). However, RGCs which are undoubtedly prone to glutamate-mediated cell death in vivo (see 
chapter 5.2) were reported to be only weakly susceptible to glutamate excitotoxicity (Hartwick et al., 
2008) or not vulnerable at all (Ullian et al., 2004) in culture. 
In this present study, the purity of seeded RGCs was 80-90%, less than compared to the original 
isolation method where the purity was reported to be around 99%. Within 24 hours, a portion of 
these cells died as observed by EthD1 labelling. The vast majority of surviving cells had large nuclei 
with extending neurites, morphologically characteristic of RGCs but not of other retinal cell types 
(Figure 4.8.A). The presence of forskolin (an external substitute for cyclic adenosine monophosphate; 
cAMP), BDNF and CNTF in the culture medium was shown to be essential for cell viability (Figure 
4.8.B-C). The necessity for their presence in the culture medium where axotomized RGCs are kept, 
has been already reported (Meyer-Franke et al., 1998). The beneficial effect on RGC survival 
following axonal transection was seen if cAMP was pharmacologically increased in the presence of 
growth factors (Shen et al., 1999; Hellström et al., 2011). This protective effect in isolated RGCs is 
attributed to co-operation between cAMP and growth factors in rapid recruitment of tyrosine kinase 
receptor B (TrkB) to the plasma membrane (Meyer-Franke et al., 1998). 
RGC loss was not observed in response to 24 hour treatment with glutamate-glycine, in our defined 
culture conditions (Figure 4.8.1). In order to visualize if the absence of cell death is reflected in RGC 
Ca2+ dynamics following glutamate receptor stimulation, ratio-metric Fura-2 Ca2+ imaging was 
performed. In these experiments, different glutamate receptor agonists were used (glutamate-
glycine, NMDA, AMPA; Figure 4.8.2.A). The intracellular Ca2+ increase immediately after the agonist 
addition was the highest in the case of glutamate-glycine and NMDA stimulation (Figure 4.8.2.B.iii). 
This implies that, at least in culture, the majority of extracellular Ca2+ following RGC stimulation is 
mediated via NMDA receptors. Delayed Ca2+ levels were observed to positively correlate with the 
initial Ca2+ increase (Figure 4.8.2.iv). However, in the vast majority of cells delayed Ca2+ levels were 
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never as high as observed in the few cases when the phenomenon of DCD was observed (Figure 
4.8.2.A). Further on, only the cells in which DCD was observed were labelled with annexin V-Alexa 
Fluor 594 conjugate (author’s observation, data not shown).  
Expression of different NMDA receptor subtypes have been confirmed in RGC culture (Ullian et al., 
2004). However, current influx following NMDA receptor stimulation was shown to be significantly 
lower compared to the levels recorded in hippocampal cells (Ullian et al., 2004). Besides, the 
presence of BDNF in the culture media, an anti-apoptotic factor (Almeida et al., 2005; Melo et al., 
2013) and modulator of synaptic NMDA receptor activity (Hildebrand et al., 2016), could suppress 
RGC degeneration following prolonged glutamate receptor stimulation.  
 
5.4 Role of NCX1 in Ca2+ dynamics following glutamate receptor 
stimulation in cultured RGCs 
The role of NCX following glutamate receptor stimulation in isolated neuronal cultures has been 
mostly addressed following AMPA receptor stimulation and in the context of DCD phenomenon 
(Hoyt et al., 1998; Bano et al., 2005; Araujo et al., 2007; Brittain et al., 2012). One of the hypotheses 
behind these studies is that DCD starts once a cell is overloaded with intracellular Na2+, and 
subsequently the new Na+ gradient forces the NCX to operate in reverse-mode. This idea originated 
from studies on isolated axons, where a loss of saltatory conduction, ATP depletion, and re-
distribution of Na+/K+-pump, leads to axonal Na2+ overload and NCX reverse-mode activity (Stys et al., 
1997; Craner et al., 2004a and 2004b). 
Data on the expression of Ca2+-related channels in acutely isolated and cultured RGCs showed a 
significant increase in the level of NCX1 mRNA expression in cultured RGCs (Table 4.8.3). This finding 
is consistent with the described role of NCX1 in neurite outgrowth (Secondo et al., 2015), a process 
that is extensive in cultured RGCs (Figure 4.8.A). However, we also wanted to investigate if NCX1 
affects RGC Ca2+ influx/extrusion following glutamate-glycine stimulation, using the reverse-mode 
NCX blocker, SEA0400 (Figure 4.9; Matsuda et al., 2001). In parallel with intracellular Ca2+ increase, 
glutamate-glycine stimulation of cultured RGCs induced a significant increase in Na+ intracellular 
levels (author’s observation using SBFI ratio-metric Na+ dye, data not shown) that might drive NCX 
into its reverse-mode of action. SEA0400 was added to the imaging solution and subsequently RGCs 
were stimulated with glutamate-glycine. A dose-dependent decrease in Ca2+ responses were 
observed following glutamate-glycine stimulation of cells pre-treated with SEA0400 (Figure 4.9.C.iv).  
The reverse-mode blocker SEA0400 was reported to have an IC50 value of 30 nM in neurons (Matsuda 
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et al., 2001) and in data presented here, a significant Ca2+ decrease was observed starting from 100 
nM SEA0400 concentrations. This observed decrease, though significant, was not as effective as that 
observed with blockade of VGCCs following glutamate-glycine stimulation (Hartwick et al., 2008). 
These results suggest the possibility that most NCX1 receptors are either inactive or operate in the 
forward-mode following glutamate-glycine stimulation of cultured RGCs. This might be explained by 
the insufficient Na+ and Ca2+ electrochemical gradient across the plasma membrane and also the 
efficiency of other channels, such as Na+/K+ pump, Na+-voltage channels, VGCCs and PMCAs in 
dealing with glutamate-glycine-induced depolarization.   
 
5.5 SEA0400 blocker application during iAON did not protect RGCs 
The kinetics and the mode of operation of NCX are highly dependent on the experimental conditions 
of isolated plasma membranes (Blaustein & Lederer, 1999). In the living cell, besides ion 
concentration inside/outside of the cell and the presence of other plasma membrane channels, 
intracellular factors additionally affect NCX physiology – either directly, such as cAMP (Menè et al., 
1993) or indirectly, such as PKC/PKA pathways that affect Na+/K+-pump (Beguin et al., 1994).   
Interest in the role of NCX in neurodegenerative mechanisms originated from studies of axonal 
damage following oxygen deprivation and subsequent failure of Na+/K+-pump because of insufficient 
ATP and further axonal Ca2+ increase via axolemal NCX activity (Stys et al., 1992a, 1992b, 1993; 
Waxman et al., 1994). The additional observations that a reduction in Na+ influx protected axons in a 
spinal cord injury model, supported the role of NCX in Ca2+-mediated axonal injury (Agrawal & 
Fehlings, 1996; Hains et al., 2004) and in EAE (Kapoor et al., 2003; Lo et al., 2003; Bechtold et al., 
2004).  
During iAON, MK801 treatment was shown to be protective of RGCs (see chapter 5.4). One of the 
possible mechanisms involved in RGC degeneration might be chronic activity of the NMDA receptor, 
prolonged depolarization, Na+ influx and NCX reverse-mode of operation. However, application of 
SEA0400 reverse-mode blocker did not have any protective effect on RGC survival during iAON 
(Figure 4.9.A). The same was observed in the optic nerve, where no change in the G/F-actin ratio was 
detected between control and SEA0400 treated groups (Figure 4.9.B). Preliminary experiments 
following intravitreal co-injection of glutamate and SEA0400 resulted in similar observations where 
no effects in either RGC survival or the G/F actin ratio decrease compared to IVI of glutamate alone 
(author’s observation, data not shown). Since NCX1 expression was confirmed in adult acutely 
isolated RGCs (Table 4.7), the treatment inefficiency most probably reflects that NCX1 reverse-mode 
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of operation is not involved in the potential mechanism of NMDA receptor-mediated RGC loss in 
iAON. However, it should be taken into consideration that the dose regime was not efficient enough. 
As presented in this study, SEA0400 was not effective in iAON, but it might still have neuroprotective 
effects during cAON. In this disease stage, SEA0400 might induce axonal salvage following 
demyelination, when axonal loss is assumed to be initiated in the similar manner as in the axonal 
oxidative damage injury discussed above. 
 
5.6 Summary 
In summary, the study presented in this thesis was based on observations previously reported in the 
induction phase in the animal model of the AON - the loss of RGCs and the ultra-structural changes in 
the axons in the absence of myelin disruption. Both observations correlated with the subtle BRB and 
BBB leakage as well as the increased microglial activation in the retina and in the ONH (Fairless et al., 
2012). In parallel with these findings, Ca2+ increase and calpain activity were observed (Hoffmann et 
al., 2013). Since gross pathology in the optic nerves was not observed during iAON, the hypothesis 
was that the early neuronal insult, independent of primary demyelination, might originate within 
areas lacking myelin, that is, the retina and ONH. The possibility that axonal transport deficits 
accompany the observed ultra-structural changes was based on the potential vulnerability of axons 
within the ONH. RGC axons are naturally unmyelinated in this part of the optic nerve and are in direct 
contact with potentially harmful influences. However, axonal transport deficits were not observed 
during iAON in either the ONH or distal parts of the optic nerve. Furthermore, the rationale was to 
address macroscopic parameters that would reflect ultra-structural axonal changes (G/F-actin ratio) 
and to address how they may correlate with RGC loss. In parallel with restructuring of the actin 
network, the Ca2+-activated actin binding protein gelsolin and also the actin globular monomer were 
affected starting from iAON. Both of them are shown to be substrates for caspases (Kothakota et al., 
1997; Sokolowski et al., 2014) and this further suggested that axonal structural changes are 
interconnected with apoptotic death pathways initiated in RGCs (Fairless et al., 2012). 
Among other possibilities, the origin of RGC loss in iAON was assumed to be connected with the 
phenomenon of glutamate excitotoxicity. The glutamate intra-retinal increase in iAON may come 
from the reported BRB leak and reactive glial cells (microglia and astrocytes) in the retina (Fairless et 
al., 2012). If so, the ionotropic NMDA receptor was suspected to be the most important mediator of 
RGC loss, predominantly because of its Ca2+ permeability and assumption that intracellular Ca2+ 
overload contributes to RGC loss (Hoffmann et al., 2013). In naïve animals, IVI of glutamate was used 
as a model for retinal glutamate increase. RGC loss and actin structure changes observed in this 
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model were comparable to the findings in iAON. This observation further initiated a treatment study 
during iAON with the NMDA receptor blocker MK801. The IVI application of MK801 was shown to be 
neuroprotective during iAON in both retina, where RGC counts were higher than in the untreated 
animals, and in optic nerves, where actin network parameters reversed to values comparable to 
healthy animas (Figure 5.6).   
 
 
 
 
 
 
In conclusion, this study provides further evidence that NMDA receptor activity within the visual 
system contributes to early neurodegeneration of RGCs in AON. Collectively with other studies, there 
is an emerging consensus that glutamate excitotoxicity plays a role in neuroinflammatory diseases 
such as MS. This is of great importance, since it is now appreciated that neurodegenerative processes 
in MS are more widespread than primary demyelination and significantly contributes to on-going and 
irreversible disability in MS patients. In light of the fact that to date only immunomodulatory 
treatments are available, with limited neuroprotective effects, the search of neuroprotective 
therapies should be a major aim for future studies. 
Figure 5.6. MK801 neuroprotection during iAON. Sheme representing MK801 protective effects on RGCs, 
in possible Ca
2+
-related manner. Blockade of retinal NMDA receptors increases RGC survival and restores 
axonal actin network parameters to the levels comparable to healthy animals. 
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Abbreviations 
AD Alzheimer’s disease 
ALS Amyloid lateral sclerosis 
AMPA α-amino-3-hydroxyl-5-methyl-isoxazol-4-propionic acid 
AON Autoimmune optic neuritis 
APP Amyloid precursor protein 
ATP Adenosine triphosphate 
Aβ β-amyloid protein 
BBB Blood-brain barrier 
BN Brown Norway 
BRB Blood-retinal barrier 
cAON Clinical phase of autoimmune optic neuritis 
CDMS Clinically diagnosed MS 
CIS Clinically Isolated Syndrome 
CNS                                Central nervous system 
CSF Cerebrospinal fluid 
EAE Experimental autoimmune encephalomyelitis 
ER Endoplasmic reticulum 
F-actin Filamentous actin 
FC Fast component axonal transport 
G-actin Globular actin (monomer) 
GM Grey matter 
HLA – DRB1 DR beta 1 gene 
iAON Induction phase of autoimmune optic neuritis 
IL2R Interleukin‑2 receptor 
IL7R Interleukin-7 receptor 
INL Inner nuclear layer 
iNOS Inducible nitric oxide synthases 
IVI Intravitreal injection 
Kif21B Kinesin family member 21B 
LGN Lateral geniculate nucleus 
MAG Myelin-associated glycoprotein 
MBP Myelin basic protein 
MHC                              Major histocompatibility complex  
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MOG Myelin oligodendrocyte glycoprotein 
MS                                 Multiple sclerosis 
NaV Voltage-gated Na+ channels 
NAWM Normal-appearing white matter 
NCX Na+-Ca2+ exchangers 
NFH Neurofilament medium 
NFL Neurofilament light 
NFM Neurofilament medium 
NFs Neurofilaments 
NMDA N-methyl-D-aspartate 
NMDAR                         N-methyl-D-aspartate receptor 
NO Nitric oxide 
ON Optic neuritis 
ONH Optic nerve head 
PD Parkinson’s disease 
PI3K Phosphoinositide 3-kinase 
PLP Proteolipid protein 
PMCA Plasma membrane Ca2+ ATPases 
PPMS Primary Progressive MS 
RGC Retinal ganglion cell 
RIS Radiologically Isolated Syndrome 
RNFL Retinal nerve fibre layer 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
RRMS Relapsing remitting MS 
SC Slow component axonal transport 
SPMS Secondary Progressive MS 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labelling 
VGCC Voltage-gated Ca2+ channels 
WM White matter 
βAPP β-amyloid precursor protein 
 
 
 
